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Vision is our most essential sense and plays a critical role in every stages of our life. 
Everyone, if they live long enough, will experience at least one eye condition during their 
lifetime. While some eye conditions do not typically cause vision impairment, such as eyelid 
inflammation, conjunctivitis or dry eye syndrome, others can cause severe visual defects. 
Among these deleterious eye conditions, uncorrected refractive error, cataract, age-related 
macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR) are the major causes 
of vision impairment worldwide [1]. Globally, it is estimated that at least 2.2 billion people 
live with a vision impairment, in which for 1 billion of these cases, vision impairment could 
have been prevented or has yet to be addressed [2]. Humans are fairly unique in their reliance 
on sight as the dominant of the five senses, since most of the information about our 
surrounding environment is gained thanks to the eyes. Eye conditions, despite causing no 
death, can thus dramatically affect life quality of patients, both at the professional and 
personal sides.  
Anti-angiogenic drugs emergence resulted in great and unprecedented advances in AMD 
and DR clinical management during the past decades [3]. Local administrations of anti-
angiogenic molecules now allow possible disease progression control. However, these drugs 
show efficiency limitations in disease control and still, no cure for AMD and DR are 
available. Thus, the development of new innovative molecules is needed to overcome this 
unmet clinical need. MicroRNAs are recently arose non-coding RNAs whose implications 
have been demonstrated in a large panel of pathological conditions. These short RNA 
molecules emerge thus as promising candidates for drug development. In recent years, 
several clinical trials started to evaluate microRNA inhibition or overexpression strategy in 
pathologies such as cancer, wound healing and viral infection [4, 5]. To date, microRNA as 





















Aims and outline of this thesis 
 
This project is the result of a collaborative work between Maastricht and Liège 
universities. The aims of this thesis are: 1) to evaluate the potential of ZSF1 rat as a model 
of diabetic retinopathy, 2) to identify dysregulated microRNAs in animal models of DR and 
AMD and 3) to explore whether the modulation of promising microRNA candidates 
identified under 2) is able to influence choroidal neovascularization.  
 
In Chapter 1 - MicroRNAs in the eye, key concepts -, we introduce, review and 
summarize the current knowledge on every concept needed for a comprehensive reading of 
subsequent chapters, microRNAs being the common thread between sections. A focus is 
made on their biology, their implication in the developing and adult eye, as well as in the 
pathological eye and finally, their role in microglia cells. 
 
The results section is subdivided in the 3 following chapters: 
In Chapter 2 - Resistance to Retinopathy Development in Obese, Diabetic and 
Hypertensive ZSF1 rats: an exciting model to identify protective genes -, we demonstrate 
that the ZSF1 rat model, despite showing hyperglycemia and hypertension, failed to develop 
diabetic retinopathy. We next highlight a potential gene network that could prevent ZSF1 
rats from developing DR. 
In Chapter 3 - MicroRNAs expression profile in diabetic patients and Akimba mice -, we 
reveal an expression profile of microRNAs in human and mouse samples and discuss their 
potential as biomarkers or therapeutic targets in DR. 
In Chapter 4 - Intravitreal injection of anti-miRs against miR-142-3p reduces 
angiogenesis and microglia activation in a mouse model of laser-induced choroidal 
neovascularization -, we provide experimental evidence that miR-142-3p is specifically 
overexpressed in CNV lesion in a mouse model of choroidal neovascularization. We next 
demonstrate that this microRNA is able to activate microglia cells both in vitro and in vivo. 
 
Finally, in Chapter 5 - General discussion -, we set our results in the general context of 
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MicroRNAs (miRNAs or miRs) are cross-kingdom short non-coding RNAs about 20-
24 nucleotides in length that are involved in post-transcriptional regulation of gene 
expression in animals, plants and microbes [1]. First discovered in the worm Caenorhabditis 
elegans during the year 1993 by Lee and colleagues [2], microRNAs are now known to be 
expressed by viruses, bacteria, algae, plants, fungi and animals, including humans [3]. The 
number of mature miRNAs identified in human is currently 2693 (miRbase, July 2020), 
many of them being expressed in a tissue-dependent or time-dependent manner. By 
regulating over than 60% of gene expression, it is well established that human miRNAs play 
fundamental roles in both development and adult life, as well as in healthy and pathological 
states [4, 5]. Non-coding RNA dysregulation, including microRNAs, is associated with 
cancer [6], cardiovascular diseases [7] and many ocular diseases, as supported by a growing 
body of evidences concerning microRNA complications in eye disorders [8, 9]. This chapter 
aims at introducing each concept that will be used and discussed in the present manuscript, 
using microRNAs as a guideline. Thus, a brief summary of basic aspects of microRNA 
biology, with a particular focus on miR-142 is first proposed. In a second time, basic aspects 
of age-related macular degeneration (AMD) and diabetic retinopathy (DR) as well as their 
regulation by microRNAs will be described. Finally, a focus on microglia, which have been 
part of this work, will be presented. 
 
 
MicroRNA biology  
 
• MicroRNA biogenesis  
Mature, and thus functional, microRNAs are processed from precursor RNA molecules 
called primary or pri-miRNA, which are transcribed by RNA polymerase II from miRNA 
genes (canonical miRNAs) (Figure 1) [10, 11]. Each canonical pri-miRNA is a substrate for 
Microprocessor, a heterotrimeric complex made of Drosha endonuclease and its partner 
protein DGCR8. Each stem of a pri-miRNA is cut by one of the two RNase III domain of 
Drosha, liberating thus a ~60 nucleotides stem-loop called pre-miRNA. Of note, non-
canonical miRNAs bypass Microprocessor and are directly transcribed into a pre-miRNA 
from protein-coding gene introns. After export from the nucleus to the cytoplasm through 
Exportin 5 and Ran-GTP, hairpin pre-miRNAs resulting from both canonical and non-
canonical undergo further processing by Dicer, another endonuclease with two RNase III 
domains. Dicer and its partner protein TRBP cut both strands near the loop to generate the 
miRNA duplex, a 20-23 nucleotides double stranded RNA molecule. One strand of this 
duplex will constitute the mature miRNA while the other strand is its passenger strand 
(miRNA*). Once formed, the miRNA duplex is loaded into an Argonaute (AGO) protein 
assisted from chaperone proteins in an ATP-dependent manner. At that time, passenger 
strand is expulsed from the duplex because of its less adapted 5’ terminus to bind to 
Argonaute, and the mature silencing complex is formed with the mature miRNA. Once 
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et al., 2010), implying that biologists interested in exploring
miRNA functions should focus on only miRNA annotations
that satisfy the stringent criteria, based on either existing or
newly acquired high-throughput sequencing data.
MicroRNAs are grouped into families based on their targeting
properties, which depend primarily on the identity of their
extended seed region (miRNA nucleotides 2–8) (Bartel, 2009).
For example, mice and humans each have three members of
the miR-1/206 seed family (miR-1-1, miR-1-2, and miR-206),
which are paralogous miRNAs that arose through duplication
of an ancestral gene inherited from a common ancestor of all bi-
laterian animals. Indeed, members of the same seed family are
usually evolutionarily related, and evolutionarily related miRNAs
are usually members of the same seed family. However, the use
of the term ‘‘family’’ does not strictly denote common ancestry.
For example, miR-32, which is not related to other members of
the miR-25/32/92/363/367 seed family, is nonetheless an adop-
ted member because it has converged on the same extended
seed and thus has the same targeting preferences. Other
miRNAs, such as miR-200a and miR-200b, which are clearly
Figure 1. The Biogenesis and Function of Canonical miRNAs of Animals
(A) Biogenesis and function of a typical miRNA. Once transcribed by Pol II, the pri-miRNA folds back on itself to form at least one distinctive hairpin structure
(further described in Figure 2), which is cleaved byMicroprocessor (purple arrowheads, cleavage sites) to release a pre-miRNA (P, 50 phosphate). The pre-miRNA
hairpin is exported to the cytoplasm through the action of Exportin 5 and RAN–GTP. In the cytoplasm, the pre-miRNA is cleaved by Dicer (blue arrowheads,
cleavage sites) to produce a !20 bp miRNA duplex with a 50 phosphate (P) and a 2 nt 30 overhang on each end. One strand of the miRNA duplex, the mature
miRNA (red), is loaded into the guide-strand channel of an Argonaute protein (AGO) to form a silencing complex, whereas the other strand, the miRNA* (blue), is
degraded. Within the free silencing complex, miRNA nucleotides 2–5 (upward red vertical lines) are poised to initially interact with target RNAs (blue; filled circle,
cap; AAAAA, poly(A) tail). This pairing usually extends to nucleotide 7 or 8 of the miRNA, and occasionally is more extensive (Figures 5 and 6). If pairing is very
extensive, the target can be sliced (left; black arrowhead, cleavage site), whereas if it is not, the target can undergo other types of repression (right; further
described in Figure 4).
(B) Typical sources of canonical miRNAs. Most canonical miRNAs derive from the introns or exons of noncoding primary transcripts, some of which harbor
hairpins for more than one miRNA. In addition, many canonical miRNAs derive from introns of pre-mRNAs.
22 Cell 173, March 22, 2018
loaded into the silencing complex, the mature miRNA pairs to complementary sites within 
mRNA and other transcripts to express their post-transcriptional regulation. Interestingly, 
once loaded into the silencing complex, most miRNAs are more stable than mRNAs, 
exhibiting half-life of days [12]. 
Of note, miRNA* strands are not systematically degraded [13], and can also be loaded 
in silencing complex. Since 2012, a novel classification of miRNAs has been made, replacing 
the old miRNA/miRNA* nomenclature by more accurate miRNA-3p/miRNA-5p one 
(Figure 2). For most of the microRNAs, both 3p and 5p arms have a biological function and 


































Figure 1. Metazoan microRNA biogenesis and function 
Pri-miRNA are transcribed by RNA Pol II from miRNA gene and are then cleaved by Microprocessor,  
heterotrimeric complex composed of Drosha and DGCR8. The resulting pre-miRNA hairpin is next exported 
from the nucleus to the cytoplasm via Exportin 5 and Ran-GTP. In the nucleus, pre-miRNA are further 
processed by Dicer to form a miRNA duplex. This duplex is loaded into an AGO protein and the passenger 
strand (in blue) is released, forming thus the silencing complex. This silencing complex finally pairs to 
complementary sites within the 3’ UTR region of target mRNA and expresses its post-transcriptional repression 
by either mRNA destabilization or translational repression. 
Adapted from Bartel (2018) 
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and has pro-atherogenic effect in human vessels (Huaman
et al. 2015). Identification of LTBI infection-related miR-
NAs in human macrophages showed that miR-296-5p was
significantly increased than the uninfected cells (Meng et al.
2014; Zheng et al. 2015). Type 1 and type 2 diabetes are
associated with an enhanced inflammatory state and
that inflammatory cells contribute to atherosclerotic
lesion initiation and lesion disruption (Kanter et al.
2008). Reddy and colleagues found that miR-296 was
upregulated in db/db VSMC compare to db/+ VSMC
via small RNA-sequencing (Reddy et al. 2016). How-
ever, the function of miR-296, especially its role in ath-
erosclerosis, has not been extensively studied.
MiR-296 has many bioinformatics targets that have
been predicted and biologically validated in human and
mouse (Table 1), suggesting that miR-296 has a wide range
of potential biological functions. In this overview, we sum-
marized the current knowledge regarding the potential
roles of miR-296 in atherosclerosis (Table 2) and tried to
provide a basis for future investigation and expand our in-
sights into miR-296 functions in atherosclerosis.
MiR-296 in angiogenesis
Neovascularization in atherosclerotic lesions plays an
important role in plaque growth and instability (Camaré
et al. 2017). MiR-296 belongs to the family of “angio-
mirs” due to its functions associated with angiogenesis
(Würdinger et al. 2008). MiR-296 and angiogenesis were
significantly upregulated following cerebral ischemic injury
(Feng et al. 2015). The formation of capillary-like structures
of human umbilical vein endothelial cells (HUVEC) was
markedly enhanced by adenovirus-mediated overexpression
of miR-296 (Feng et al. 2015). The sequence-specific inhib-
ition of miR-296 by intravenous injection of cholesterol-
conjugated antagomir can reduce neovascularization in a
mouse tumor model (Würdinger et al. 2008).
The vascular endothelial growth factor (VEGF) and
Notch signaling pathways are crucial in angiogenesis that
is promoted by VEGF and inhibited by Notch under most
developmental or pathological conditions (Kim et al. 2017;
Mao and Meng 2017). Overexpression of miR-296 was ob-
served to increase the expression levels of VEGF and vas-
cular endothelial growth factor receptor 2 (VEGFR2) and
simultaneously reduce the expression levels of delta-like
ligand 4 (DLL4) and Notch1 (Feng et al. 2015). One of the
miR-296 targets is hepatocyte growth factor-regulated
tyrosine kinase substrate (HGS). MiR-296 can reduce the
levels of HGS and HGS-mediated degradation of VEGFR2
and platelet-derived growth factor receptor-β (PDGFR-β)
(Würdinger et al. 2008). VEGFR and PDGFR are the tar-
gets of anti-angiogenic therapies (Batchelor et al. 2007;
Shih and Holland 2006). The Notch pathway lies down-
stream of the VEGF signaling, and the activation of VEGF
signaling increases the expression of Notch ligands DLL4
(Liu et al. 2014; Lobov et al. 2007). This finding is contra-
dictory to the research showing that miR-296 promotes
VEGF signaling and inhibits the Notch pathway. It is pos-
sible that there is another target gene for miR-296, which
downregulates the expression of DLL4 and Notch. Further
research is needed to elucidate the mechanisms by which
miR-296 regulates the angiogenesis.
MiR-296 in inflammatory response
MiR-296 regulates NF-кB pathway
In miR-296 overexpressed HCT116 cells, western blot
analysis showed that nuclear transcription factor-κB
(NF-κB) P65 protein was decreased, while the pP65 level
was elevated with enhanced nuclear import. On the con-
trary, NF-κB P65 level was decreased in cells with low
expression of miR-296 (Zhai et al. 2016). Therefore, these
findings suggest that miR-296 plays an important role in
regulating NF-κB signaling pathway.
In mammals, there is a Numb homolog called “Numb-
like” or NumbL, that is a cytoplasm protein and has redun-
dant functions in embryonic neurogenesis. The studies have
shown that overexpression of NumbL can inhibit NF-κB
Fig. 1 The structure of the 80 nt pre-miR-296 (pre-miR-296) precursor and mature miR-296. a Homo sapiens stem-loop structure of pre-miR-296.
Two different mature miRNAs are produced from this precursor: miR-296-5p (sequence in blue) and miR-296-3p (sequence in red). The orientations (5′
to 3′) are indicated by the direction of the arrows. b Mature sequence of hsa-miR296-5p and hsa-miR296-3p


















• MicroRNA regulatory mechanis s 
MicroRNAs recognize and repress their target transcripts through two alternative modes, 
depending on pairing coverage. If pairing between the microRNA and its mRNA target is 
sufficiently extensive, and if the microRNA is associated with an AGO protein, then the 
miRNA directs slicing of the target [16]. This first repression mode is common for plant 
miRNAs [17] but only a few cases of direct slicing have been reported in human [18]. The 
repression mode that dominates in human s slicing-i ependent and does not r quire an 
extensive pairing coverage. Instead, it requires an adaptor protein, TNRC6, recruited by 
AGO, interacting with the poly(A)-binding protein PABPC associated with the mRNA 
poly(A) tail an  recruiting i s lf a de denylaze c mplex [19]. This latest complex short ns 
the poly(A) tail, which causes mRNA destabilization through decapping and 5’-to-3’ 
exonucleolytic decay. Besides transcriptional repression, TNRC6 recruitment also causes the 
mRNA to be less efficiently translated due to in ibition of translation initiatio . The relative 
importance of TNRC6-mediated transcriptional or translational repression depends on the 
developmental context of the cell, mRNA transcriptional repression dominating in post-
embryonic cells. Thus, in mamm ls, regardless the miRNA, cell type or growth condition, 
mRNA destabilization explains 66-90% of miRNA-mediated repression [20]. 
Transcriptional repression of mRNA target mediated by TNRC6 is triggered by Watson-
Crick pairing between the miRNA se d sequence (miRNA nucl otides 2-8) and sites within 
the 3’-UTRs of target mRNAs [21]. Thus, it is possible to predict putative targets by 
computational methods [22]. Most of these methods rely on algorithms implemented with 
information such as but not limit d t  the miRNA sequence, the 3’UTR of mRNA, the seed 
sequence, thermodynamics parameters, the miRNA 3’ site and the conservation status of 
both miRNA and mRNA sequence [23]. Bioinformatics has thus become a powerful tool for 
lgorithmic t rget prediction with online free datab ses such a  TargetScan, miRTarBase and 
Figure 2. MicroRNA-5p and microRNA-3p derived from the same pre-miR 
Structure of the pro-angiogenic and pro-inflammatory miR-296, both miR-296-5p and miR-296-3p being 
produc d from pre-miR-296.  
Adapted fr m Li (2018) 
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miRDB [22, 24, 25]. However, experimental confirmation using luciferase reporter assays 
remain the golden standard for a biological validation of predicted mRNA targets. 
 
• Regulation of microRNA expression 
While regulating gene expression, microRNAs themselves are also subject to a tight 
temporal and spatial expression and production control. MicroRNAs processed from the 
introns of mRNAs are under the same transcriptional regulation as the mRNA of their host 
gene [26]. All other canonical miRNA loci are also under RNA Pol II transcriptional control, 
indistinguishable from that of protein-coding gene [27]. Once the miRNA locus has been 
transcribed, diverse regulatory factors can influence either the stability or processing of 
individual hairpin molecule. In addition, multiple regulatory mechanisms influence the 
accumulation and activity of both Microprocessor and Dicer [28]. 
MicroRNA abundance and stability are also regulated by miRNA decay, but it has not 
extensively been studied so far. A target-directed miRNA degradation mechanism (TDMD) 
has been suggested [29]. In this mechanism, the complementary RNA target promotes 
degradation of its miRNA, accompanied by post-transcriptional modification of the miRNA 
sequence, i.e. tailing (addition of nucleotides at the 3’ end) and trimming (shortening), and 
unloading from AGO [30]. While some miRNAs show half-life of days once associated to 
AGO [12], other miRNAs are not so stable. For example, some neuronal miRNAs have 
variable stability and a few are constitutively unstable, enabling a more rapid response to 
transcriptional changes [31]. Triggering of TDMD mechanism by different features could 
explain some of the differences observed in endogenous miRNA stability [32]. 
 
• MicroRNA impact on gene regulation and biological functions 
MicroRNAs are considered as fine-tuners of gene expression rather than on-off 
regulators [33]. A single mature microRNA species may potentially target hundreds of 
mRNA molecules. Therefore, dysregulated miRNA expression can disrupt RNA networks 
that are otherwise tightly regulated. However, while repressing hundreds of target mRNAs, 
protein level of miRNA targeted gene are only slightly influenced by the modulation of 
microRNA expression as revealed by proteomic analysis [34]. MicroRNAs thus act through 
an assembly of slight perturbations which may be a favorable aspect for their use as 
therapeutic targets. This “one hit – multiple targets” appeared to be a promising therapeutic 
concept but this inherent particularity of microRNA complicate the identification of 
microRNA targets that explain the observed phenotype [35]. While some microRNA target 
sets are enriched in specific cellular function such as the oncogenic miR-17~92 cluster with 
enriched targets enrolled in growth control [36], most of microRNAs seem to influence 
diverse biological functions. In the same way, many specific biological functions are 
regulated by several microRNAs simultaneously. The field of microRNAs biological 
function study has been explored via the use of knock-out and mutant animals, including 
nematode, fly and mouse. D. P. Bartel extensively reviewed all current literature about 
metazoans microRNAs [10]. Thus, many microRNAs are required for proper development 
of skeleton, teeth, brain, eyes, neurons, muscle, heart, lungs, kidneys, vasculature, liver, 
 19 
pancreas, intestine, skin, fat, breast, ovaries, testes, placenta, thymus and each hematopoietic 
lineage. MicroRNAs are also important for many cellular functions and physiological 
processes. 
These functional particularities of microRNAs lead to many successes in determining 
their general mechanisms of function, but microRNA application in translational area has not 
had much success yet [37]. In 2019, only 7 microRNAs (miR-16, miR-21, miR-29, miR-34, 
miR-92, miR-122 and miR-155) were therapeutic candidates in clinical development, with 3 
reaching phase II and the other ones still in phase I [38, 39]. 
 
• Experimental microRNA inhibition and overexpression 
MicroRNA functions have been largely described through the use of gain or loss of 
function strategies. While different genetic knock-out or knock-in animal models have been 
implemented to decipher microRNA functions, the use of different kind of inhibitors or 
enhancers of microRNA expression is also extensively used in experimental work [40] 
(Figure 3). 
On one hand, microRNA inhibition can be performed through the use of different 
molecules such as but not limited to antagomiR, LNA (Locked Nucleic Acid) antimiR and 
miR mask [41]. AntagomiRs are single-stranded RNA molecules conjugated with 
cholesterol, either at the 3’ or 5’ terminus, and 21-23 nucleotides in length. Complementary 
to their target miRNA, they bind to it thus preventing the miR-mediated repression of the 
target mRNA. Once intercepted by the antagomiR, miRNA is either degraded or stabilized 
in a miR-antagomiR duplex. LNA antimiRs present a methylene bridge between the 2’-O 
and the 4’-C atoms, locking thus the ribose ring. This chemical enhancement results in an 
increased potency, safety and binding affinity [40]. LNA antimiRs are shorter than 
antagomiRs, covering miRNA seed sequence and are made of either single stranded RNA or 
DNA molecules. Finally, miR-masks are single stranded 2’-O-methyl modified antisense 
oligonucleotides complementary to miR target sequence on mRNA 3’UTR. These 
oligonucleotides thus prevent the miRNA binding to a specific target gene. 
On the other hand, microRNA overexpression is possible through the use of different 
expression systems. Thus, conventional pri-miR or pre-miR are available, as long with 
mature miR expression systems [42]. Mature miR expression systems, often referred as to 
miR mimics, are chemically synthetized double-stranded RNA that can easily transfected in 
host cells. 
At the experimental level, assessing the efficiency of miRNA inhibition and 
overexpression can sometimes be tricky. Indeed, microRNA inhibitors do not always induce 
the degradation of their miRNA targets, also possibly protecting them from cellular 
degradation. For both inhibitor and enhancer molecules, effect on the mRNA can also be 
different, depending on the miRNA itself. Assessing miRNA inhibition and overexpression 
should be thus done by evaluating the level of miRNA and mRNA, at both the transcript and 
















































Figure 3. Experimental miRNA inhibition and overexpression 
While miRNA inhibition can be performed through the use of antagomiRs, LNA antimiRs or miR-masks, 
miRNA overexpression is possible through the use of miRNA mimics. AntagomiRs and LNA antimiRs bind 
to the full miRNA sequence and only to its seed sequence, respectively. MiR-mask directly bind to mRNA 
sequence targeted by specific miRNA. Mature miRNA mimic are synthetic molecule “mimicking” endogenous 
miRNA. 
Adapted from Dang (2015) and Fan (2019) 
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• Focus on miR-142: 
In the subsequent section, a focus on miR-142 will be made since this specific 
microRNA is the key component of Chapter 4 and part of Chapter 3. With only 13 hits on 
PubMed in 2009 with the key word “miR-142”, microRNA-142 was part of 189 publication 
titles in 2020. In 10 years, this specific microRNA has been studied in a large context of 
diseases and its roles in both physiological and pathological conditions only start to be 
elucidated, emerging as a critical regulator of many biological processes. 
MiR-142 gene is encoded in chromosome 17 in human and in chromosome 11 in mouse. 
In both species, miR-142 gene is an intronic microRNA located a few kb upstream 
TSPOAP1, a gene encoding for a benzodiazepine receptor associated protein (NCBI genomic 
database, July 2020). It is associated in a cluster with miR-4736, a poorly described 
microRNA. Interestingly, human, mouse and rat versions of mature miR-142-3p and miR-
142-5p are fully conserved, suggesting recurrent functions and allowing possible translation 
of rodent to human results. Mature miR-142-3p is a 23-base long oligonucleotide with a 35% 
GC content, generated from an 87-nucleotide long hairpin in human and a 64-nucleotide long 
hairpin in mouse. Mature miR-142-5p is two nucleotides shorter with 33% GC content. 




































































emerged as pivotal gene-expression regulatory molecules in
multicellular organisms. The founding member of microRNAs is
lin-4. It was the first microRNA discovered to play a regulatory role
in the transition from one larval stage to another in the nematode
Caenorhabditis elegans. It does that by translation repression of
lin-14 gene involved in the larval development programs (Bartel,
2004). MicroRNAs are encoded in several ways such as indepen-
dent transcription units, in the introns of pre-mRNAs, or multi-
cistronic clusters. The suppressive action of microRNAs on their
target genes can be achieved in many ways. If there is perfect
complementarity between the microRNA binding sequence and
the seed region on the untranslated region of the mRNA, mRNA
transcripts undergo cleavage and degradation. In contrast,
imperfect base pairing results in translational inhibition at the
level of initiation and elongation of mRNA (Bartel, 2009; Stefani
and Slack, 2008). One essential feature of microRNAs is that
their suppressive function is not limited to one-microRNAdone-
mRNA paradigm. In fact, one microRNA can target multiple mRNA
targets, and conversely, one mRNA can be targeted by multiple
microRNAs(Bracken et al., 2016). Hundreds of microRNAs have
been cloned and discovered in many organisms till date. There-
fore, to understand gene expression regulation, spatiotemporal
regulation of microRNAs is an active field of research. Diverse
functional roles of many of these microRNAs have been delineated
in a variety of physiological and pathological conditions (Lin and
Gregory, 2015; O'Connell et al., 2010; Sayed and Abdellatif, 2011;
van Rooij and Olson, 2012).
Majority of microRNAs display a ubiquitous expression, but a
few are more enriched in specific tissues than others. The pre-
microRNA-142 has the signature stem-loop structure, which en-
codes for two microRNA species (miR-142e3p and miR-142e5p).
Both miR142e5p and -3p are well conserved in many species
including mouse, rat and human (Fig. 1) (Griffiths-Jones, 2004;
Griffiths-Jones et al., 2006, 2008; Kozomara and Griffiths-Jones,
2011, 2014). MiR142 is essentially expressed in hematopoietic tis-
sues (Chen et al., 2004). Its primary role in hematopoietic tissue
was discovered to be lineage differentiation (Merkerova et al.,
2008). Over the years, plenty of literature has emerged that
collectively underscores the role of miR-142 in immune and in-
flammatory response. Although, studies have also explored diverse
functional effects of miR-142 in different biological conditions, the
critical regulatory role of miR-142 on different aspects of immunity
remain predominant.
2. MiR-142 is a hematopoietic tissue-enriched microRNA
MiR-142 (miR-142e3p and miR-142e5p) is preferentially
expressed in hematopoietic tissues. Chen et al. made the very first
attempt to characterize the hematopoietic tissue-richmicroRNAs in
mice. Their study shows that miR-142 is enriched in the adult he-
matopoietic tissues: bone marrow, spleen and liver, and fetal liver,
an embryonic hematopoietic organ (Chen et al., 2004). Many
transcription factors (TFs) such PU.1, Runx, C/EBP, GATA, PAX5,
Ikaros, and FLI1 are involved in the differentiation lineage of he-
matopoietic cells. These TFs regulate gene expression changes
specific to hematopoiesis. To explore the mechanisms governing
specific expression of miR-142 in hematopoietic cells, Sun et al.
demonstrated that the promoter of miR-142 contains separate
binding sites for three TFs, PU.1, C/EBPb, and Runx1 only in the
hematopoietic cells. Of these, PU.1, either alone or in synergy with
C/EBPb and Runx1, has a predominant role in driving the expres-
sion of miR142 (Sun et al., 2013). This study identifies the upstream
elements that are important for driving miR142 expression in he-
matopoietic cells, thus modulating many immune regulatory
functions of miR-142 as discussed in this review.
2.1. MiR-142 is involved in lineage differentiation of hematopoietic
cells
Mildner et al. characterized the different cells of myeloid lineage
based on their differential microRNA expression. Their study spe-
cifically focused on mononuclear phagocytes that are involved in
multiple aspects of innate and adaptive immunity. In particular,
microRNA signatures were identified in three bone marrow
myeloid precursor subsets, monocytes, plasmacytoid dendritic cells
(pDC) and splenic classic dendritic cells (cDCs). Interestingly,
miR142 is highly expressed in cDCs, most prominently in CD4þ DCs.
In a murine model, with splenic deficiency of miR-142 in DC, many
costimulatory molecules were activated causing disruption of DC
homeostasis. Thus, high expression of miR-142 in DC population
appears to be crucial for homeostasis and tonic function of DCs
(Mildner et al., 2013).
Since then, many scientific studies have shown agreement
between the hematopoietic origin of miR142 with its functional
regulation of hematopoiesis. MiR142e3p was shown to play a
pivotal role in the lineage differentiation of hematopoietic stem
cells (HSCs) in zebra fish. Its loss led to defects in HSC differen-
tiation. This study identified interferon regulatory factor 7 (irf7)
as the direct functional target of miR142e3p, and concluded that
miR142-3p-irf7 inflammatory axis is potentially involved in
lineage differentiation of HSCs in zebrafish. Similar findings in
the HSCs development were discovered in mice, reinforcing the
conserved role of miR142e3p (Lu et al., 2013). Along similar
lines, miR142e3p positively regulates the monocytic and gran-
ulocytic differentiation, commonly referred to as myeloid differ-
entiation. MiR142e3p promotes myeloid differentiation by
suppressing the expression of its target TGF- betaeactivated ki-
nase 1/MAP3K7 binding protein 2 gene (TAB2). In the context of
disease relevance, abnormal expression of miR142e3p leads to
blockage of myeloid differentiation, a major characteristic of
acute myeloid leukemia (AML) (Wang et al., 2012). Thus, these
studies provided conclusive evidence in support of miR-142's
role in hematopoiesis.
Fig. 1. Pre-miR-142 encodes miR-142e5p and -3p microRNAs. A. Mature forms of miR-142 are conserved in mouse, rat and human. B. Stem-loop structure of human pre-miR-142.
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associated protein 1 (Bzrap1, ENSMUSG00000034156) is also another gene found downstream
ofmiR-142. ThemiR-142 locus also contains many GC-rich repeat regions, which render PCR
amplification and screening difficult. The constitutive and complete deletion of themiR-142
gene was therefore carried out andmiR-142 heterozygous mice were generated. Fig 2B shows
the genotyping results of E18.5 embryos arising from crossingmiR-142 heterozygous mice. Fig
2C shows the validation of our primer sets to amplify either the wild typemiR-142 allele (P2/
P3), the presence of the LoxP site (P1/P4) or themiR-142-null allele (P1/P3).
Fig 1. Schematic Representation of themiR-142 locus in the mouse genome.miR-142 gene is located
in the vicinity of an exon belonging to a LncRNA (A430104N18Rik ENSMUSG00000084796) on
chromosome 11. Deletion ofmiR-142 led to the deletion of the LncRNA exon as well as part of the 5’ UTR of
Bzrap1. LncRNA: Long non-coding RNA. Bzrap1: Benzodiazepine receptor (peripheral) associated protein 1.
doi:10.1371/journal.pone.0136913.g001
Fig 2. Genotyping Strategy formiR-142 KO allele. A) Schematic diagram showing theWT, targeted and
KO alleles for themiR-142 locus. P1, P2, P3 and P4 represent the primers used to genotype wild type and
KO alleles.B-C) PCR analysis of the genomic DNA obtained from the embryos at E18.5 frommiR-142+/-
male and female intercrossing. 254 bp band size for KO allele (Primers used: P1 and P3) and 174 bp band
size for WT allele (Primers used: P2 and P3) was determined. A 105 bp band was observed using LoxP
specific primers (P1 and P4).
doi:10.1371/journal.pone.0136913.g002
MiR-142 Knock Out Mice
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dent transcription units, in the introns of pre-mRNAs, or multi-
cistronic clusters. The suppressive action of microRNAs on their
target genes can be achieved in many ways. If there is perfect
complementarity between the microRNA binding sequence and
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microRNAs(Bracken et al., 2016). Hundreds of microRNAs have
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fore, to understand gene expression regulation, spatiotemporal
regulation of microRNAs is an active field of research. Diverse
functional roles of many of these microRNAs have been delineated
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Gregory, 2015; O'Connell et al., 2010; Sayed and Abdellatif, 2011;
van Rooij and Olson, 2012).
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Griffiths-Jones et al., 2006, 2008; Kozomara and Griffiths-Jones,
2011, 2014). MiR142 is essentially expressed in hematopoietic tis-
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was discovered to be lineage differentiation (Merkerova et al.,
2008). Over the years, plenty of literature has emerged that
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elements that are important for driving miR142 expression in he-
matopoietic cells, thus modulating many immune regulatory
functions of miR-142 as discussed in this review.
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based on their differential microRNA expression. Their study spe-
cifically focused on mononuclear phagocytes that are involved in
multiple aspects of innate and adaptive immunity. In particular,
microRNA signatures were identified in three bone marrow
myeloid precursor subsets, monocytes, plasmacytoid dendritic cells
(pDC) and splenic classic dendritic cells (cDCs). Interestingly,
miR142 is highly expressed in cDCs, most prominently in CD4þ DCs.
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nase 1/MAP3K7 binding protein 2 gene (TAB2). In the context of
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acute myeloid leukemia (AML) (Wang et al., 2012). Thus, these
studies provided conclusive evidence in support of miR-142's
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Figure 4. Genomic location and sequences of miR-142 hairpin and mature microRNA 
A. MiR-142 gene is located within chromosome 17 in human and chromosome 11 in mouse, a few kb upstream 
TSPOAP1 gene and in the vicinity of an exon belonging to a lncRNA. 
B. Stem-loop structure of the hairpin pre-miRNA-142 containing both miR-142-5p sequence (in red) and miR-
142-3p (in blue). 
C. Alignment of mouse, rat and human pre-miR-142, showing fully conserved sequences and seed sequences 
(green boxes). 
Adapted from Shrestha et al. (2015) and Sharma (2017) 
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MiR-142 exhibits functions in development, homeostasis and disease, with a particular 
role in hematopoietic system regulation [43]. It was first identified in hematopoietic stem 
cells by Chen and colleagues [44] and was than further described for its critical role in 
zebrafish during the formation and differentiation of hematopoietic stem cells and progenitor 
lineages [45, 46]. Two teams have generated either miR-142 knockdown (KD) or knockout 
(KO) mice to further unveil miR-142 biological function in vivo. First, Chapnick and 
colleagues developed a miR-142 KD mouse strain, using exogenous gene trap technology 
[47]. They reported a critical role of miR-142 during megakaryopoiesis. MiR-142 KD caused 
impaired megakaryocyte maturation, inhibition of polyploidization, abnormal platelet 
formation and thrombocytopenia. Platelet formation was altered due to a poorly controlled 
actin filament homeostasis in the absence of miR-142. One year after Chapnick, Shrestha 
and team generated miR-142-null mice using homologous recombination [48]. Embryonic 
miR-142 null mice exhibit increased Wnt signaling in lungs while pups were born alive and 
were normally represented, indicating an absence of any embryonic lethality. Adult miR-
142-null animals were viable and displayed impaired hematopoietic lineage formation. 
Taken together, Chapnick and Shrestha’s results strongly argue for a critical function of miR-
142 during hematopoiesis. However, both KD and KO mice generated exhibit either a strong 
decrease or an extinction of both miR-142-3p and miR-142-5p, making an impossible 
distinction between each strand specific functions. Later on, several new functions have been 
described for both miR-142 mature forms. Thus, evidences suggest a possible mechanism by 
which miR-142 may play an important role in maintaining stem cell pluripotency during 
organogenesis [49]. In addition of keeping a bimodal state in stem cells, miR-142 seems to 
be implicated during lung development by decreasing proliferation of mesenchymal cells and 
premature differentiation of smooth muscle progenitor cells [50]. Besides its role during 
development, miR-142 is also downregulated during cardiac hypertrophy, a normal 
mechanism possibly resulting in heart failure under hypertension conditions [51]. MiR-142 
also exhibits several functions related to immune response and immune tolerance. Thus, a 
high level of miR-142-3p was observed in the peripheral blood mononuclear cells from 
immune tolerant renal transplanted patients [52]. Furthermore, both miR-142 mature forms 
are associated with several cancer types. Thus, miR-142-3p level in cervical cancer epithelial 
cells was significantly lower than in healthy cervical epithelial cells, indicating a regulatory 
impact of miR-142-3p in cervical cancer [53]. MiR-142-3p was also found to inhibit tumor 
progression and invasion in hepatocellular carcinoma cells [54]. On the other hand, miR-
142-5p overexpression correlates with cancer progression by suppressing growth inhibition 
of cancer cells [55]. Thus, miR-142 implication in cancer is thus poorly understood and 
seems to be cancer-type specific. Finally, recent publications focusing particularly on miR-
142-3p show that this specific microRNA is associated with a wide range of inflammation 
and neovascularization associated diseases such as breast cancer [56], neuroinflammation 
[57], gestational diabetes mellitus [58] and uveal melanoma [59]. Also, miR-142-3p 
expression was found to be upregulated in a mouse model of retinal degeneration [60]. It is 
now clear that both miR-142-3p and miR-142-5p are critical regulators of several 
physiological process, mainly hematopoiesis and play a role in a wide variety of diseases. 
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Because of their status of recently described microRNAs, miR-142-3p and miR-142-5p 
biological functions are currently emerging. In regard of the growing number of publications 
concerning miR-142, one can hypothesize that this microRNA has probably still many 
unknown functions. However, it is now clear that both mature microRNAs have distinct but 
also shared properties. A deeper analysis of current literature reveals that mRNA targets of 
miR-142 are not well described. Indeed, compared to well-studied microRNAs such as miR-
155 targeting SOCS1 mRNA and miR-146a targeting IRAK1 and TRAF6 mRNAs, both 
mature forms of miR-142 are still lacking conserved targets that could be studied in a wide 
range of cell types and tissue types. Thus, human miR-142-3p most cited targets in the 
literature are ARNTL and RAC1 (miRTarBase, July 2020). Further characterization of 
































MicroRNA in the developing and adult eye 
 
The eye is a complex and specialized sense organ responsible of the conversion of a light 
signal into electro-chemical impulses through the nervous system. Despite structural 
differences through species, molecular biology has now provided supportive evidences 
suggesting that the eye has arisen a single time during evolution. Thus, the involvement of 
highly conserved transcription factors such as PAX6 in the genetic control of eye 
development in organisms ranging from planarians to human, strongly argue for a 
monophyletic origin of the eye [61]. Eye development is dictated by conserved genes 
throughout the animal kingdom, giving rise to diversified ocular structure, from basic forms 
such as pit eyes to near-to-perfect human eye [62]. The human eye is made up of three coats, 
which enclose the optically clear aqueous humor, lens and vitreous body. The outermost coat 
consists of the cornea and the sclera; the middle coat contains the main blood supply to the 
eye and consists, from the back forward, of the choroid, the ciliary body, and the iris. The 
innermost layer is the retina, lying on the choroid and receiving most of its nourishment being 
derived from the retinal vessels (Figure 5A). The retina is a complex nervous structure, being 
an outgrowth of the forebrain. It is made of specialized cells such as retinal pigmented 
epithelial (RPE) cells, photoreceptors (i.e. rod and cone cells), bipolar neurons and ganglion 
cells but it also contains more generic cells such as endothelial cells and inflammatory cells 
(including microglia cell) (Figure 5B). Of note, most of the eye components are free from 
lymphatic vasculature excepted for corneal limbus, ciliary bodies and lacrimal glands. 
Despite lymphangiogenesis is known to play important role during corneal transplantation 
and ocular tumor progression, its importance in most eye diseases is currently unknown [63]. 
Because vertebrate eye development is tightly regulated by a specific gene expression 
pattern, it is not surprising that microRNAs are major actors during ocular organogenesis. 
While deletion of miR-302 in mice results in a late embryonic lethal phenotype, abnormal 
eye development can be observed in miR-302 null mice from E13.5, suggesting a critical 
role of this specific microRNA in ocular organogenesis [64]. The miR-183/96/182 cluster is 
a sensory organ specific microRNA, known to regulate maturation of sensory organs and 
diseases such as cancer and autoimmune disorders [65]. This cluster is highly expressed in 
mouse retina and its inactivation results in early-onset and progressive synaptic defects of 
the photoreceptors and progressive retinal degeneration [66]. Further studies demonstrated 
that ablation of only two of the three members of the cluster, miR-183 and miR-96, 
significantly affects photoreceptor maturation and maintenance [67]. Other microRNAs such 
as miR-124a and miR-211 have been identified as critical regulators of cone photoreceptor 
function and survival, leading to altered visual function when deleted [68, 69]. 
Besides their role during eye development and photoreceptor maturation, microRNAs 
are also important for eye homeostasis by regulating major eye specific cell types physiology 
such as photoreceptors, RPE cells, ganglion cells and keratocytes [70]. MicroRNAs 
implication in eye homeostasis is further confirmed by the huge population of microRNAs 
expressed in human and mouse eye as revealed by deep sequencing analysis. Thus, Soundara 
and colleagues showed that 320 different microRNAs are expressed in mouse retina, while 
 26 
choroid/RPE complex expresses 340 microRNAs [71]. In a similar way, Karali demonstrated 
an even greater number of microRNAs expressed in human retina and choroid/RPE complex, 
with 480 and 416 detected microRNAs, respectively [72]. In mouse, a microRNA expression 
atlas of the eye (miRNeye project) was made by a combination of microarray analysis and 
RNA in situ hybridization, providing insights into microRNA profile at the tissue level in 
WT mice (embryonic stage E16.5 and post-natal days P0, P8 and P60) [73]. This atlas reveals 
that microRNAs are expressed in all eye tissues, with specific or not expression patterns 
during development and adult life. Concerning microRNA expression in the vitreous fluid, 
it is suggested that vitreal microRNAs may result from either retinal cell excretion (via 
exosomes or microvesicles) or from resident vitreal cells (phagocytes or hyalocytes - cells 
responsible for the production of structural vitreal molecules -) in non-pathological 
conditions [74]. Under pathological conditions, vitreal microRNAs may be produced by 
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1. INTRODUCTION
Microglia, the primary resident population of innate immune cells in the neural parenchyma, is a
key constituent of the glial populations in the central nervous system (CNS). Formerly mysterious
and largely ignored, microglia have over the last decade been discovered to play crucial roles in
the CNS that extend beyond more traditional concepts of immune defense to functions in CNS
development and homeostasis (Kierdorf & Prinz 2017). Significantly, studies of CNS pathology
have found microglia to be centrally involved in pathogenic mechanisms in multiple neurodegen-
erative diseases (Salter & Stevens 2017), prompting investigation into new therapeutic strategies
for which microglia constitute the central cellular target (Peña-Altamira et al. 2017).
In the retina, microglia similarly constitute a prominent part of the resident glial population.
Microglia in the adult retina resemble those throughout the CNS in their ramified morphology
and dynamic process motility (Lee et al. 2008). However, they possess some distinguishing features
in the laminated structure of the retina, such as their distribution as horizontal arrays of cells that
are concentrated in the synaptic plexiform layers of the inner retina and their interactions with
specialized glia and neurons, such as Müller cells and photoreceptors (Figure 1). While there are
fewer studies specifically examining microglia in the retina than elsewhere in the CNS, the retina
represents an advantageous and unique system for studying microglia. The close juxtaposition of
retinal microglia with orderly arrays of retinal synapses in the plexiform layers can facilitate the
study of microglia-synapse interactions. Microglia in the retina are uniquely optically accessible
without intervention and can be directly and noninvasively examined using in vivo fundus imaging.
Lastly, the ability to evoke neuronal responses in the retina by visual stimuli that can be measured
with electroretinography enables neuron-microglia interactions in neural circuits to be studied
under natural conditions. As such, while microglia in the retina may possess specialized differences,










Distribution and morphology of microglia within the laminated retina. (a) Cross-section of the adult mouse
retina, showing microglia (labeled with Iba1) distributed in a laminar pattern in the inner plexiform and
outer plexiform layers (IPL and OPL, respectively), alongside vascular plexi (labeled with IB4). Microglial
distribution is largely excluded from the outer retinal layers, such as the outer nuclear layer (ONL).
(b,c) En-face views of microglia in flat-mounted retinal tissue as horizontally ramified cells that tile the IPL













































































Scheme H&E staining Fluorescent IHC 
A 
B 
Figure 5. Basic anatomy of the human eyeball and structure of its posterior pole 
A. The human eye is a near-to-spherical organ. The sclera is the external thick conjunctive tissue which at its most 
anterior region forms the cornea. The intraocular pressure is maintained thanks to the vitreous humor, a highly 
hydrated gel. The lens allows light refraction to the light-sensitive part of the eye, the retina. The choroid, lying 
between the sclera and the retina, is a vascular tissue responsible of retina maintenance. 
B. The retina is a multilayer tissue composed of, from inner to outer region, inner limiting membrane (Müller cell 
endfeets), nerve fibre layer (ganglion cell axons), ganglion cell layer (GCL), internal plexiform layer (IPL, synapses 
between bipolar, amacrine and ganglion cells), internal nuclear layer (horizontal, bipolar and amacrine cell bodies and 
Müller cell nuclei), external plexiform layer (OPL, synapses between photoreceptors, bipolar and horizontal cells), 
external nuclear layer (ONL, photoreceptor cell bodies), external limiting membrane (junctions between Müller cells 
and photoreceptors), retina pigmented epithelium (RPE) and Bruch’s membrane.  
Microglia (Iba1 stained, in green) cell bodies are located within the IPL and OPL, with protrusions extending in 
adjacent layers, and are in close contact with blood vessels (IB4 stained). 
Fluorescent immunohistochemical (IHC) section is adapted from Silverman and Wong (2018). 
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MicroRNA in the pathological eye 
 
As for many other organs, microRNAs are critical drivers of the correct development 
and homeostasis of the human eye but are also implicated in several ocular pathologies. 
Every component of the eye is subjected to microRNA regulation, possibly leading to disease 
if unproperly regulated. Retina, choroid, sclera, cornea, and lens are thus the major eye 
components that can be affected by microRNA dysregulation, leading to a variety of diseases 
such as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinitis 
pigmentosa, refractive errors, cataract, uveitis, glaucoma and keratitis. In this section, a 
deeper analysis of pathophysiology of AMD and DR and their possible microRNAs 
dysregulation will be made. 
 
• Age-related macular degeneration and microRNAs 
 
Epidemiology, etiology and animal models 
Age-related macular degeneration is a progressive retinal pathology affecting the elderly 
and is the fourth leading cause of blindness worldwide [75]. With 8,7 % of worldwide 
population currently affected by AMD, a substantial increase of this percentage is expected 
due to ageing population [76]. This pathology affects the macula, the central part of the retina 
responsible for high-acuity daylight and central vision [77]. Early and intermediate stages of 
AMD are characterized by the formation of sub-RPE deposits called drusen. These serve as 
precursor stages for the evolution of late AMD, which consists of two distinct phenotypes: 
(i) geographic atrophy, characterized by progressive degeneration of the RPE, photoreceptors 
and choriocapillaries, and (ii) neovascular AMD, characterized by the formation of choroidal 
neovascularization (CNV). These two late stages are highly sight-threatening, but wet, or 
neovascular, AMD prevalence is lower than the atrophic form and represents the most sight-
threatening form. AMD etiology is complex and multifactorial, not currently fully 
understood. Main risk factors for developing AMD are increasing age, heredity and smoking 
[78]. CNV is the hallmark of wet AMD and occurs by breaking through the Bruch’s 
membrane, invading the sub-retinal space and leaking fluids and bloods from newly 
immature hyperpermeable capillaries [79]. It is the final step of wet AMD  and leads to severe 
visual loss [80]. Several animal models are available for studying wet AMD [81], but one of 
the most cited one in current literature is the laser-induced CNV mouse model [82]. This 
model relies on Bruch’s membrane perforation via laser treatment, inducing subsequent 






















































Wet AMD, also called neovascular macular 
degeneration, is the most severe form of AMD. 
About 10% to 15% of people with dry AMD will 
progress to the wet form. 
In wet AMD, blood vessels grow abnormally 
beneath the macula, through a process called 
angiogenesis. These abnormal vessels leak fluid 
and blood, which may cause a blister-like pocket to 
form beneath the macula. These blisters distort 
vision in the affected eye, making straight lines 
appear wavy. The patient may see a dark spot or 
various spots in the center of their vision. This is 
due to blood or fluid collecting under the macula. 
Unlike dry AMD, which develops slowly and in 
stages, wet AMD can rapidly progress and damage 
the macula, causing a loss of central vision. 
Periodic eye examinations are crucial for people at 
risk for wet AMD. If wet AMD is left untreated, 
bleeding in the eye can cause scar tissue to form, 
leading to irreversible vision loss. 
The good news is that there are now several 
effective, FDA approved treatments for wet AMD. 
These treatments can stabilize or, in some cases, 
reverse vision loss if used before scar tissue forms. 
“Periodic eye examinations are crucial 












Dry AMD is the most common form of AMD and 
occurs in multiple stages. In the early stages of dry 
AMD, yellow deposits known as drusen begin to 
accumulate in the back of the eye. Drusen can vary 
in size and number, and are considered a natural 
part of the eye’s aging process.
Over time, the disease can progress into advanced 
dry AMD and eventually wet AMD. In advanced dry 
AMD, the progressive increase in the number 
and/or size of drusen is accompanied by the 
deterioration of the light-sensing cells and 
surrounding tissue in the macula.  This causes 
significant vision problems.
One eye or both eyes may be affected by AMD. 
When only one eye is affected, vision loss is harder 
to detect because the “good eye” works harder to 
compensate for the affected eye.  Thus, frequent 
self eye exams and regular visits to a retinal 
specialist are needed to keep tabs on visual acuity 
in both eyes.
WHAT IS AMD?
Age-related macular degeneration (AMD) is a 
disease associated with aging that gradually 
destroys the sharp, central vision needed to 
read, recognize faces, drive a car, and in 
general see things clearly. AMD affects the 
macula, which is located in the center of the 
retina, the light-sensitive tissue at the back of 
the eye. The macula is the part of the eye 
needed to see fine details.
LEARN: The Science of AMD
Early  
pathological condition 
Figure 6. Choroidal neovascularization (CNV) is the hallmark of wet age-related 
macular degeneration 
In early AMD, while photoreceptors and choroidal vessels remain unaltered, sub-RPE deposits called drusen 
are observed and can eventually trigger AMD progression. Choroidal neovascularization is the hallmark of late 
stage neovascular (or wet) AMD and is regulated by a balance of pro- and anti-angiogenic and inflammatory 
factors, resulting in the formation of leaky blood vessels. CNV in responsible of photoreceptors and RPE 
damage, thus threatening vision. 
Adapted from The Angiogenesis Foundation (scienceofamd.org) 
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Pathophysiology  
AMD is a highly complex neurovascular disease, with a not fully described 
pathophysiology. Ageing, genetic components and environmental factors act together in the 
triggering of AMD, inducing angiogenesis and inflammatory pathways. CNV progression is 
tightly regulated by a balance of pro and anti-angiogenic factors, Vascular Endothelium 
Growth Factor (VEGF) being a key positive regulator of angiogenesis. Among all VEGF 
family members, VEGF-A and PlGF (Placental Growth Factor) have demonstrated functions 
during CNV progression, both stimulating neovascularization in animal models [83, 84]. 
Elevated levels of VEGF induce blood-retina barrier (BRB) breakdown, thus activating 
choroidal macrophage invasion of the retina. Other pro-angiogenic factors such as 
angiopoietin and HIF-1 (Hypoxia-inducible Factor-1) are also described for their 
contribution to CNV progression [85, 86]. These pro-angiogenic factors stimulating CNV 
progression are counteracted by a series of anti-angiogenic factors. Among them, PEDF 
(Pigment Epithelium-Derived Factor) is expressed in balance with VEGF, and a decrease in 
its level is permissive for AMD in human [87]. Trombospodin-1 deficient mice subjected to 
laser-induced CNV exhibited exacerbation of neovascular surface, associated with an 
increased macrophage recruitment [88]. The contribution of other molecular mediators has 
been demonstrated in CNV progression, such as different members of the matrix 
metalloproteinase family (MMP-2, MMP-9 and MMP-13) and plasminogen activator 
inhibitor type-1 (PAI-1) [89-91]. 
Besides this tight regulation of pro and anti-angiogenic factors and even if AMD is not 
clinically considered as a classical inflammatory disease, many mechanisms of inflammation 
are involved during AMD onset [92]. The eye used to be considered as an immune privilege 
site. It is not sheltered from intraocular inflammation but has developed to limit it, so as to 
protect the delicate visual elements from damage that would be detrimental to visual acuity 
and therefore survival [93, 94]. Thus, the retina disposes of its own endogenous 
immunocompetent cells, microglia and dendritic cells, dealing with other eye immune cells 
such as macrophages and neutrophils. Production of inflammatory-related molecules, 
complement activation, recruitment of macrophages and microglia activation are thus the 
predominant mechanisms involved. Under normal aging conditions, the retina undergo a 
low-grade inflammation referred as parainflammation. Parainflammation is defined as a 
condition of tissue adaptive response to noxious stress or malfunction, and it has features 
which are considered as intermediate between normal/basal and inflammatory/acute states. 
While the physiological role of normal parainflammation is to preserve tissue homeostasis 
and to restore their function if exposed to prolonged stress, parainflammation is also 
implicated in both initiation and progression of many human age-related disorders, such as 
obesity, atherosclerosis and AMD [95, 96]. Triggers of detrimental parainflammation in the 
retina are oxidative stress and oxidative species, oxidized lipoproteins, lipid peroxidation by-
products, advanced glycation end products (AGEs) and apoptotic cells [97]. Once triggered, 
detrimental parainflammation is responsible for complement system activation. The role of 
this innate immunity cascade reactions was initially suggested as a driver of wet AMD when 
complement components where found in drusen of AMD patients [98]. Since this discovery, 
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many studies highlighted a highly significant correlation between AMD and polymorphism 
of gene encoding several molecules involved in complement pathway such as CFH, CFB and 
C2 [99, 100]. Although inflammatory processes involved during AMD are only partly 
elucidated, inflammation seems to be tightly associated with angiogenic processes during 
age-related macular degeneration progression. 
 
Clinical management 
Due to its highly complex and still not totally understood etiology, AMD was hardly 
treated until early 2000. First only treated by photodynamic therapy [101], neovascular AMD 
treatment has been largely enhanced during the last decades thanks to anti-VEGF therapy. 
Different anti-VEGF drugs emerged on the market, with efficiency improvement from 
generation to generation. The first anti-VEGF drug approved by the FDA was pegaptanib, a 
PEGylated short RNA oligonucleotide targeting VEGF165  [102, 103]. A few years after 
pegaptanib, two antibodies, namely bevacizumab (Avastinâ) and ranibizumab (Lucentisâ), 
targeting all VEGF-A isoforms and their receptor-binding domain, respectively, emerged as 
the standard procedure for AMD treatment [104, 105]. One of the latest anti-VEGF drug 
market-released is a dimeric recombinant fusion glycoprotein targeting a broad range of 
VEGF family members, aflibercept (Eyleaâ) [106]. Finally, brolucizumab (Beovuâ) was 
FDA and EMA approved for the management of neovascular AMD in 2019 and 2020, 
respectively. Brolucizumab is a humanized single-chain variable fragment antibody 
inhibiting all VEGF-A isoforms, with a lower molecular mass when compared to other drugs, 
allowing thus a higher solubility and tissue-penetration [107, 108]. Unfortunately, despite 
this revolution of exudative AMD treatment, around one fifth of neovascular AMD patients 
are non-responsive or show a really poor response to anti-VEGF therapy [109], highlighting 
the need of an improvement of actual therapy. Of note, none drug is available at the moment 
for the treatment of geographic atrophy, the late stage of dry AMD. Several candidates are 
currently being tested in clinical trials, mainly focusing on either anti-inflammatory or 
neuroprotective therapy [110]. 
 
MicroRNA implication 
The next big step in AMD treatment could eventually be achieved with microRNA 
therapy, but to reach this challenging goal it will imply a much deeper understanding of 
microRNA regulation of AMD. To date, several studies have focused on establishing 
microRNAs has potential biomarkers or therapeutic targets in AMD in both human and 
mouse study.  
In human, all researches conducted are mainly profiling studies focused on determining 
a microRNA expression profile in human samples. Most of the studies focused on circulating 
microRNAs extracted from either whole blood [111, 112], plasma [113, 114] or serum [115, 
116]. Circulating microRNAs are extracellular microRNAs, sometimes exosome 
encompassed, and recognized as an exciting new avenue of research for many pathologies 
[117, 118]. Unfortunately, these studies show great inconsistencies within the most 
dysregulated microRNAs and almost no replication is observed between these independent 
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works. One can hypothesized that heterogenous patient cohorts and detection methods are 
the main factors that could explain these inconsistencies. Besides peripheral-blood 
circulating microRNAs, some studies have also focused on much more difficult to access 
samples. For example, Ménard and colleagues identified several neovascular AMD-specific 
microRNAs is the vitreous of diseased patients, with a reproducible expression pattern in 
plasma [114]. Thus, miR-146a-5p increased while miR-106b-5p and 152-3p decreased in the 
vitreous and plasma of wet AMD patients. Unfortunately, only miR-146a-5p overexpression 
was confirmed in other similar studies [115]. Pogue and colleagues showed an up-regulation 
of 7 inflammatory microRNAs, including miR-146a, in retinas of post-mortem AMD 
patients [119]. Interestingly, these microRNAs were also up-regulated in brains of post-
mortem Alzheimer disease patients, another neurogenerative disease sharing some features 
with AMD.  
In rodent, both profiling and functional studies have been mainly done on mouse models 
of CNV. A recent study by Kiel and colleagues showed a microRNA expression profile of 
both circulating as well as retina and RPE-choroid complex tissue microRNAs in a laser-
induced CNV mouse model [120]. Both miR-486a-5p and miR-92a-3p exhibited a decreased 
expression in blood while their expressions were higher in RPE-choroid complexes and not 
changed in retinas when compared to control condition. Interestingly, both microRNAs 
showed an impact on murine microglia cell viability in in vitro functional assays. In another 
similar study, expression patterns of microRNAs and transfer RNA-derived small RNAs 
(tsRNAs) from laser-induced CNV mouse model RPE-choroid-sclera complex were 
investigated [121]. Here the authors found that miR-10a-3p and miR-1247-5p were the most 
up and down regulated in CNV model, respectively. Unfortunately, no commonly 
dysregulated microRNAs were jointly highlighted in this study and Kiel’s. Despite laser-
induced CNV mouse model is the most frequent model, intravitreal injection of amyloid-b 
(A-b) is sometimes used for A-b elicited disease such as neurodegenerative disease and 
glaucoma [122, 123]. This in vivo model of AMD has been designed on the basis of previous 
reports showing the presence of A-b deposits in drusen of AMD patients [124, 125]. Romano 
and colleagues showed an up-regulation of miR-27a, miR-146a and miR-155 in retinas from 
A-b-elicited AMD rat [115]. It is not surprising to observe that both miR-146a and miR-155, 
two well-described pro-inflammatory microRNAs, are up-regulated in AMD rats. 
Concerning miR-155, divergent results have been found by two distinct teams in a laser-
induced CNV mouse model. While Zhang and colleagues reported a decrease of CNV area 
in mice intravitreally injected with miR-155 mimic [126],  Zhuang and colleagues reported 
the same phenotype but with miR-155 inhibitor [127]. These conflicting findings may result 
in the different timing used for CNV area calculation as the first team measured CNV area 7 
days after laser induction while the other measured 14 days post induction. Surprisingly, 
downregulation of an endothelial-cell specific microRNA, miR-126 [128], was observed 
during CNV progression and subsequent intravitreal injection of miR-126 mimic 
successfully decreased vascular phenotype [129]. Finally, a functional role in CNV 
progression was also determined for the well-studied let-7 microRNA family [130]. Let-7 
transgenic mice exhibit exacerbated expression of let-7a, d and f members and were less 
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prone to CNV compared to WT mice under laser induction. Concomitantly, subretinal 
delivery of let-7 inhibitor increased CNV progression in WT mice. 
Taken together, these different studies of microRNA implication in AMD strongly 
support the hypothesis of a functional regulation of AMD by short non-coding RNAs. 
However, many inconsistencies exist between studies, even when methodological 
procedures only slightly differ. Furthermore, opposite functions have also been demonstrated 
for a single microRNA during CNV progression, drawing a veil on its true biological function 
in a CNV context. Only extensive combination of new human and animal model studies will 
allow to tightly decipher microRNA regulation in AMD, and thus eventually be the starting 


































• Diabetic retinopathy and microRNAs 
 
Epidemiology, etiology and animal models 
Diabetes Mellitus (DM) is one of the fastest growing chronic disease worldwide, 
affecting 463 million individuals in 2019 and excepted to affect 693 million by 2045 [131, 
132]. Diabetes can lead to severe complications in many organs, including the eye. Thus, 
diabetic retinopathy (DR) is a major complication of diabetes, affecting the retina and 
possibly leading to vision impairment and vision loss. DR affects 35,4% of all-type diabetic 
patients and is the fifth leading cause of blindness worldwide [133]. While worldwide DR 
prevalence in type-1 DM patients is estimated to range from 10 to 50 %, with great variations 
between countries, it is estimated that about 25% of type-2 DM patients suffer from DR. DR 
is a neurovascular pathology triggered by hyperglycemia, affecting different cell-type of the 
retina and involving several biochemical modifications [134]. It can be classified as non-
proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR) and 
diabetic macular edema (DME). While NPDR is not sight-threatening, PDR form is 
characterized by retinal neovascularization, a process leading to severe vision impairment. 
The risk factors for developing DR are glycated hemoglobin, hypertension, dyslipidemia, 
diabetes duration, ethnic origin, pregnancy, puberty and cataract surgery [135]. At the 
experimental level, different animal models of DR exist such as the streptozotocin (STZ)-
induced rodent models, the db/db mouse, and the Akimba mouse showing severe retinal 
neovascularization. All above mentioned models showing their own limitations [136, 137]. 
Thus, there is still a need for new animal models reflecting every stages of DR progression.  
 
Pathophysiology  
DR is a highly complex neurovascular disease with a not fully understood 
pathophysiology. As for AMD, the two main biological processes driving DR are 
angiogenesis and inflammation and are not independent, but rather interacting processes 
which share several mediators and signaling pathways [138-140] (Figure 7). 
Hyperglycemia is responsible for the initiation of molecular and cellular complications, 
ultimately leading to sigh-threatening endpoints, i.e. PDR and DME. By triggering several 
biochemical abnormalities, hyperglycemia induces the overproduction of mitochondrial 
superoxide in vascular endothelial cells and leads to increased flux through the polyol 
pathway, overactivity of the hexosamine pathway, activation of the protein kinase C (PKC) 
and the accumulation of AGEs [141]. These pathways increase the levels of intracellular 
reactive oxygen species (ROS), and thus oxidative stress, inducing inflammation, vascular 
hyperpermeability, neuroglial dysfunction and microvascular dysfunction. The levels of pro-
inflammatory cytokines and chemokines such as TNF-alpha, IL-beta, IL6, iNOS and ICAM1 
are elevated in DR eyes [142]. Thus, inflammation has pivotal functions in the initiation and 
progression of DR. In diabetic retinas, leukostasis might damage endothelial cells and 
neuroglial cells by physical occlusion of capillaries and through the release of inflammatory 
mediators [143]. This results in a loss of endothelial cells (ECs) and pericytes, subsequently 
leading to microaneurysms, acellular capillaries and hypoperfusion. Besides the 
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all of these pathways (Brownlee, 2005; Nishikawa et al., 2000).
While the complexity of these pathogenic pathways is beyond
the scope of this article and are reviewed elsewhere (Antonetti,
Klein, & Gardner, 2012; Stitt, Lois, Medina, Adamson, & Curtis,
2013), it is relevant to contextualise these inter-connected pro-
cesses and their links to the pathologies outlined above (Fig. 4).
8. Conclusion
The complex pathology observed in the diabetic retina reflects
the inter-connected nature of all the component cells in this neural
tissue. An evolving body of evidence based on clinical pathology
and experimental data obtained over the last 20 years means that
there now exists an expanded view of diabetic retinopathy and
how it develops. While most current therapies remain focused on
late-stage PDR and DME, widening appreciation of the diabetes-
associated pathophysiology in the neurovascular unit should pro-
vide opportunities to prevent disease at a much earlier stage. It is
anticipated that in the coming years new pharmacological treat-
ments based on an understanding of the causative mechanisms
of diabetic retinopathy will be developed and address the need
for both vascular and neuroprotection.
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Fig. 4. Schematic overview of pathogenic mechanisms leading to the sight-threatening endpoints of DR. DR arises through a complex interplay between neuroglial and
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making up the endothelium ultimately leads to compensatory growth of new fragile and leaky blood vessels. Compromise of BRB integrity leads to the extravasation of fluid
and inflammatory mediators, creating sight threatening edema and exacerbating inflammatory conditions. Concurrent or preceding neuroglial dysfunction perpetuates
damage.
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overexpression of pro-inflammatory cytokines, VEGF expression is also upregulated in DR, 
triggered by local ischemia. Diabetic patients with either PDR or DME have elevated 
vitreous level of VEGF [144]. Elevated levels of VEGF induce neovascularization as well as 
BRB breakdown, subsequently leading to either PDR or DME. 
Among other cellular processes, initial inflammation triggering results in a subsequent 
deleterious microglia activation in the diabetic retina, leading to neurotoxicity and tissue 




































Figure 7. Pathophysiology of diabetic retinopathy 
Diabetic retinopathy is triggered by hyperglycemia, which induces diverse molecular and cellular complications 
ultimately leading to sigh-threatening endpoints. Polyol pathway, hexosamine pathway, PKC activation and AGEs 
accumulation all lead to inflammation, vascular hyperpermeability, neuroglial pathology and microvascular 
pathology, finally r sulting i  BRB breakdown and neovascularization. Neuroglial pathology is mainly 
characterized by loss of n uros and n urovascular coupling while e rly microvascular pathol gy results in EC and 
pericyte loss, overall resulting in neovasculariza on. Several inflammatory nd angiogenic mediators are 
involved, such as but not limited to TNFa, IL1-b, IL6, iNOS a d VEGF. Fi al endpoints triggered by 
hyperglycemia are PDR and DME. 
Adapted from Lechner et al. (2017) 
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Clinical management 
As DR incidence in diabetic patients increases with age, DR onset has to be strictly 
monitored through regular eye examination. Thus, it is recommended that diabetic patients 
showing no signs of DR undergo ophthalmology follow-up every 1-2 year to attest any DR 
development [134]. While mild and moderate NPDR are generally not treated, severe NPDR 
as well as PDR et DME can be partly treated. For severe NPDR, panretinal photocoagulation 
is considered for ablating ischemic neurons and glial cells in non-perfusion areas [146, 147]. 
However, despite panretinal photocoagulation can reduce the risk of developing PDR, its 
intrinsic destructive properties can cause peripheral visual field defects, reduced night vision 
and eventually exacerbates DME [148]. For PDR, panretinal photocoagulation can also 
applied to avoid vitreous hemorrhages, retinal detachment and eventually glaucoma [146]. 
Sustained vitreous hemorrhage or retinal detachment can be overcome by vitrectomy. 
Notably, the emergence of anti-VEGF therapy first designed for AMD treatment had also 
considerably improved DR clinical management. Thus, anti-VEGF therapy is now a standard 
procedure for DME and PDR treatment [149]. While bevacizumab has been used has an off-
label drug for DME management since its approval by FDA for colorectal cancer in 2004, 
ranibizumab and aflibercept were approved by the FDA for DME treatment in 2012 and 
2014, respectively [150]. Since August 2020, the BUZZARD study is currently addressing 
the safety and efficacy of brolucizumab in the treatment of DME (clinicaltrial.gov). Another 
alternative for the management of DME, notably for DME patient refractory to anti-VEGF, 
is the use of corticosteroids [149]. Several candidates are currently being tested or in 
development for DME management such as angiopoietin pathway stimulators and Rho-
associated protein kinase inhibitors [151]. 
 
MicroRNA implication 
As for AMD, the next big step in DR treatment could arose from microRNA studies, but 
to achieve this goal, an in-depth understanding of microRNA regulation of DR is mandatory. 
Several studies have currently focused on establishing microRNAs has potential biomarkers 
or therapeutic targets in AMD in both human and mouse study.  
Because vitrectomy surgery can be performed to overcome vitreous hemorrhage and 
retinal detachment in DR patients, vitreous fluid has been broadly used as a biological fluid 
for miRNA detection in human. Serum, plasma, blood extracellular vesicles, peripheral 
blood and endothelial progenitor cells have also been studied for a microRNA signature in 
DR patients. Li and Martinez recently reviewed the main findings of such studies [152, 153].  
In rodent, many studies have focused on microRNA profiling in STZ-induced rat, mainly in 
either retinas or isolated retinal endothelial cells (RECs) [154]. Streptozotocin (STZ) is a 
cytotoxic agent leading to b-pancreatic cell death, possibly leading thus to diabetes. Its 
administration to rodents (mouse or rat) is broadly used to trigger DR phenotype [155]. 
Kovacs and colleagues performed a microarray analysis on retinas and RECs from STZ-
induced rats 3 months after diabetes onset and identified a specific set of dysregulated 
microRNAs [156]. Surprisingly, retinas and RECs microRNAs profiles exhibited large 
variations, probably due to a more complex cellular population in retinas. In a similar study 
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conducted by Wu and colleagues, microRNA expression profiles in retinas of STZ-rat was 
conducted during DR progression until 10 weeks after STZ injection [157]. Interestingly, 
relative levels of miR-182, 96, 183, 211, 204 and 124 were positively correlated with DR 
progression while relative levels of miR-10b, 10a, 219-2-3p, 144, 338 and 199a-3p 
negatively correlated. Unfortunately, Kovacs and Wu profiling showed almost no overlap in 
microRNA dysregulation. Finally, Gong and colleagues profiled microRNA dysregulation 
in either human RECs or human RPE under hyperglycemic conditions and analyzed the same 
set of microRNAs in the retinas of STZ-rat over time [158]. In these studies, no functional 
analysis of specifically dysregulated microRNAs was made. Other studies aimed to 
determine a potential functional role of specific microRNA in different DR models. Among 
others, it has been thus demonstrated that miR-29a/b, miR-146a, miR-199a-3p and miR-200b 
alter DR onset in either in vitro or in vivo models [159-162]. Of particular interest is the 
opposite function of let-7 in NPDR and wet AMD [130]. While silencing of let-7 microRNA 
in the eye increased laser-induced CNV, transgenic mice overexpressing let-7 family exhibit 
characteristics of NPDR, suggesting distinct implication in the pathogenesis of DR and 
AMD. 
All together, these different studies on microRNA implication in DR strongly support 
the hypothesis of a functional regulation in the course of this pathology. However, many 
inconsistencies exist between studies, even when methodological procedures only slightly 
differ. Only extensive combination of new human and animal model studies will allow to 
tightly decipher microRNA regulation in DR, and thus eventually be the starting material for 
new performant drug design. 
 
 
• MicroRNA in other eye conditions 
 
Although microRNA implication in AMD and DR is extensively studied in the scientific 
literature, microRNA implication in many other eye conditions is also described. Thus, 
microRNAs as potential biomarkers or therapeutic tools for glaucoma, retinitis pigmentosa, 














MicroRNA in retinal microglia 
 
Glial cells are non-neuronal cells maintaining homeostasis of the central nervous system 
(CNS) and peripheral nervous system, producing myelin and providing support and 
protection for neurons. Glial cells are a cell type population composed of microglia and 
macroglia, which includes astrocytes, oligodendrocytes, ependymal cells and retina-specific 
Mullër cells. Microglia are the resident macrophages of the central nervous system (CNS), 
including the retina, and play pivotal functions in developmental, physiological and 

































Figure 8. Retina microglia cells, sentinels of the eye 
Microglia cells are the resident macrophages of the retina and are involved in both physiological and 
pathological conditions.  
A. In the healthy retina, microglia (Iba1 stained, in green) form a stable and highly ordered network of ramified 
cells, closely linked to the vascular network (IB4 stained, in red), with their cell bodies located both at the inner 
plexiform layer (IPL) and outer plexiform layer (OPL). Flatmounted retina, adapted from Silverman and Wong 
(2018). 
B. Microglial cells are major actors of many retinal disease such as AMD and DR.  
Left panel: flat-mounted choroid stained for microglia cells (in green) and vascular network (in red) in the CNV 
lesion region of the laser-induced CNV mouse model.  
Right panel: transversal retinal section stained for microglia cells (in green, shown by white arrowheads) in the 
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Figure 4. Elevated expression of macrophage/microglia markers in Akimba mouse. Double immunostaining 
of Iba-1 (A–D) with OX-42 (E–H), and CD14 (M–P) with F4/80 (Q–T). Iba-1 staining (arrowheads) in WT 
(A) mice showed resident microglial cells with normal ramified morphology in the inner retina. Akita (C) 
mice showed minimal activation of microglia, however, had displaced microglia in the outer nuclear layer 
(ONL). Iba-1+ cells were both increased and amoeboid shaped in the outer retina of Kimba (B), and maximal 
activation was seen in Akimba (D) retina. OX-42 (block arrowheads) stains a cell surface antigen expressed 
by microglia, hence co-localized (arrows) with Iba-1+ microglia in WT (I). Majority of Iba-1+ microglia in 
Kimba (J), Akita (K) and Akimba (L) mice retina also stained positive for OX-42 (arrows). CD14 (arrowheads) 
is expressed by perivascular macrophages, which were minimal and located only around the vessels in the 
ganglion cell layer of the WT (M) mice. Increased expression was seen in the Kimba (N) and Akita (O) mice, 
and was drastically elevated in the outer retina of Akimba (P) mice, indicating migratory perivascular cells 





During development, microglia derive from primitive hematopoietic progenitors 
originating from the embryonic yolk sac and colonize the mouse brain and retina at E9 and 
E11.5, respectively [170, 171]. Retinal microglia colonize the retina in a radial and vitreal-
to-scleral direction, starting near the optic nerve. During colonization, microglia cells 
proliferate, maturate and gain their final branched morphology (i.e. small cell bodies with 
long cellular protrusions). In the course of development, microglia are responsible of the 
survival and death of developing retinal neurons, the shaping of neuronal circuits and the 
modeling of the retinal vasculature [172-174]. During adult life, microglia cells form a stable 
and highly ordered network of ramified cells, with their stroma located at the inner plexiform 
layer (IPL) and outer plexiform layer (OPL), and carry out constitutive maintenance 
functions in order to maintain tissue integrity [171] (Figure 8). Throughout adulthood, 
microglia constantly screen their local environment with their long protrusions for eventual 
pathogen invasion and assure neuronal activity and synaptic integrity [175]. Recent findings 
suggest that adult retina microglia cells exist as a self-sustaining, closed population in the 
absence of injury or disease, being thus able of mild proliferation [176, 177]. Retina 
microglia cells remain quiescent and insure homeostasis under the control of both RPE cells 
and neurons [178, 179], but can shift at any moment into an activated mode under 
pathological conditions. 
 
 Classical molecular markers used for the study of general microglia include CD68, 
CD11b, F4/80, CX3CR1 and Iba1 [168]. Unfortunately, these markers can sometimes also 
be expressed by peripheral macrophages and should be used with care as discrimination can 
be tricky (Figure 9A). In a recent work, Jurga and colleagues review the latest findings on 
specific general microglia markers as well as on specific activation microglia marker [180]. 
Thus, combining the use of classical marker (e.g. Iba1) and the use of expression profile of 
other markers (e.g. CD45low) may be a suitable strategy for specific microglia study. 
Microglia activation may be analyzed by both morphological parameters and molecular 
markers. This activation can be triggered by several mediators such as but not limited to 
lipopolysaccharides (LPS), tumor necrosis alpha (TNF-a), interferon gamma (IFN-g), 
diverse complement factors, extracellular ATP, amyloid-b, TGF-b, IL-4 and IL-10 [180, 
181] (Figure 9B). While morphological analysis will allow to characterize activated state 
versus quiescent state, molecular markers analysis will allow to discriminate M1 activated 
phenotype (pro-inflammatory) versus M2 activated phenotype (anti-inflammatory). 
Activation of microglia cells is thus morphologically observed as a change from a highly 
ramified shape to an amoeboid shape, showing thus a direct form-to-function relationship. 
However, this morphological change does not result in a binary state between quiescent and 
activated microglia, but rather in a wide range of intermediate morphologies, the traditional 
view of a “ramified resting” and “amoeboid activated” being overcome [182]. Different 
shape parameters have been described to study this morphological shift [183]. At the 
molecular level, activation of microglia cells can be observed through the production of 
different intracellular, surface and secretory markers (Figure 9B). Thus, M1 activated 




as long with the production of CD14, CD16, CD32, CD40, CD86 and different MHCII 
proteins. These M1 microglia will also secrete different cytokines and chemokines such as 








































Figure 9. Markers of general and activated microglia 
A. Microglia and peripheral macrophages share different molecular markers, but also have distinct expression 
patterns. Thus, microglia cells, but not peripheral macrophages, are positive for P2Y12, TMEM19, FCRL5,, 
HexB and show a low basal level of CD45. 
B. Activated microglia cells may exhibit a M1 (pro-inflammatory) or M2 (anti-inflammatory) phenotype, or any 
intermediate phenotype. Distinction between Ma and M2 phenotype is possible through the analysis of different 
secretory, surface or intracellular markers. 
Adapted from Jurga (2020). 
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Because of their activation in a broad range of neurovascular complications including 
DR and AMD, microglia as therapeutic targets could limit inflammatory changes and thus 
successfully alleviate disease progression. Thus, several inflammatory mediators linked to 
microglia activation are currently used or under investigations for clinical application. 
Synthetic glucocorticoids can bind to endogenous glucocorticoid receptor and inhibit 
activation of the innate immune system through the negative regulation of pro-inflammatory 
molecular pathways [184]. In the clinic, delivery of glucocorticoids via intravitreal injections 
or sustained-release implant have been used for the treatment of DME and retinal vein 
occlusion [185, 186]. Unfortunately, the direct contribution of microglia modulation to the 
overall effects of the therapy remains elusive. Minocycline, a tetracycline derivative, is a 
highly bioavailable agent decreasing microglia activation via mechanisms involving the 
inhibition of MAPK [187]. After showing promising therapeutic effects in multiple retinal 
disease models [188, 189], it has entered clinical trial for the treatment of DME, showing a 
modest but progressive improvement of disease [190]. 
 
MicroRNAs and transcription factors work together to orchestrate complex cellular 
events, such as monocyte-macrophage differentiation as well as microglia development and 
activation. CEBPa and PU.1 are two transcription factors known for their critical regulation 
of monocyte to macrophage differentiation and microglia development, CEBP being 
considered the master regulator of hematopoietic stem cell differentiation. On one hand, 
CEBPa transcription factor directly regulates several microRNAs, including miR-223 by 
activating miR-223 gene transcription [191]. On the other hand, PU.1 is required to promote 
the skewing of granulocyte-macrophage progenitors to the monocyte lineage. High level of 
PU.1 induce the transcription of miR-424 gene and thus avoid favoring the granulocyte 
lineage, with combinatorial regulation of miR-222 and miR-155 [192]. In addition, the miR-
17-92 cluster has been directly associated with the process of monocyte to macrophage 
differentiation [193]. Given the large similarities between macrophages and microglia, one 
can hypothesize that some of these microRNAs and transcription factors also play critical 
role in microglia differentiation. Some studies focused on the specific role of microRNA in 
the development of microglia, rather than the monocyte to macrophage differentiation. Thus, 
miR-124, one of the most abundant microRNAs in the brain, is required for the proper 
maintenance of the quiescent state of microglia in the brain, by targeting CEBPa as well as 
CDK4 and CDK6, two cyclins [194, 195]. MiR-155, a broadly described pro-inflammatory 
microRNA, targets anti-inflammatory proteins in microglia such as SOCS1, leading to the 
upregulation of several inflammatory mediators and contributing to a microglia-mediated 
neurotoxic response [196]. Several other microRNAs, such as miR-181a-5p, miR-30a and 
miR-26b-5p, have been directly linked to brain or retina microglia activation, highlighting a 
critical regulation on microglia physiology [197-199]. Of particular interest, miR-142-3p has 
been recently linked to microglia activation in rat by Gupta and colleagues [200]. The authors 
performed a microRNA microarray in LPS activated microglia derived from rat pup’s brain 
and identified miR-142-3p as the top up-regulated microRNA. In this context, they identified 
CAMK2A (Ca2+/calmodulin dependent kinase 2a) as a direct target of miR-142, a gene 
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implicated in the regulation of the expression of brain-derived neurotrophic factor and long-
term potentiation, a cellular mechanism underlying memory and learning. 
All together, these results demonstrate the prominent role of microRNAs in the 
regulation of microglial development and activation, opening new interesting opportunities 
for anti-inflammatory therapies. Further studies will have to determine how miRNA 
modulation could interfere with microglia biology in specific pathological conditions, 
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Diabetic retinopathy (DR) is one of the major complications of diabetes, which 
eventually leads to blindness. Up to date, no animal model has yet shown all the co-
morbidities often observed in DR patients. Here, we investigated whether obese 42 weeks 
old ZSF1 rat, which spontaneously develops diabetes, hypertension and obesity, would be a 
suitable model to study DR.  
Although arteriolar tortuosity increased in retinas from obese as compared to lean 
(hypertensive only) ZSF1 rats, vascular density pericyte coverage, microglia number, 
vascular morphology and retinal thickness were not affected by diabetes.  These results show 
that, despite high glucose levels, obese ZSF1 rats did not develop DR.  Such observations 
prompted us to investigate whether the expression of genes, possibly able to contain DR 
development, was affected. Accordingly, mRNA sequencing analysis showed that genes (i.e. 
Npy and crystallins), known to have a protective role, were upregulated in retinas from obese 
ZSF1 rats. 
Lack of retina damage, despite obesity, hypertension and diabetes, makes the 42 weeks 
of age ZSF1 rats a suitable animal model to identify genes with a protective function in DR. 
Further characterisation of the identified genes and downstream pathways could provide 



























Globally, prevalence of diabetes has nearly doubled from 4.7% in 1980 to 8.5% of the 
adult population in 2014 [1]. Diabetes can lead to several complications affecting the 
cardiovascular system, kidneys, nerves, and eyes [2]. Diabetic retinopathy (DR) is one of the 
most serious complications of diabetes. Prolonged exposure to high blood glucose levels 
(hyperglycemia) results in severe damage of the retinal vasculature [2-4]. This can lead to 
blurred vision, dark spots, flashing lights, and eventually total loss of vision. DR is the 
leading cause of blindness [5] and makes a big contribution to the total 11.6% of annual 
health-care costs accounted for diabetes [6].  
Currently, several animal models are being used to study the progression of DR, for 
example the streptozotocin (STZ)-induced and Akimba mouse models (reviewed in [3]). All 
these models, however, present serious limitations and they do not reflect all stages of DR 
progression in humans. In addition, these models do not develop diabetes spontaneously, but 
are either chemically or genetically induced. For instance, STZ is a toxic substance that is 
injected in mice or rats to destroy the pancreatic β-cells [3, 7]. The Akimba mouse develops 
DR due to the presence of the human Vascular Endothelial Growth Factor isoform 165 
(hVEGF165) transgene, which induces an overexpression of VEGF in photoreceptors [8]. 
Among the few established animal models that develop diabetes spontaneously, the Zucker 
Diabetic Fatty (ZDF) rat represents an established model for type 2 diabetes. However, ZDF 
rats did not show any clear sign of DR, i.e. vascular occlusion or regression [9]. Besides the 
ZDF, the obese ZDF/Spontaneously Hypertensive Heart Failure (SHHF) F1 hybrid (ZSF1) 
rat, which are the result of a cross between a ZDF female and a SHHF male, develops 
metabolic complications typical of type-2 diabetes and have a more severe phenotype than 
the ZDF parental strain. Both obese and lean control ZSF1 rats are hypertensive [10]. 
However, the obese ZSF1 rats are also affected by diabetic nephropathy (DN), insulin 
resistance, obesity, hyperinsulinemia, hypercholesterolemia, congestive heart failure, and 
hypertriglyceridemia [11]. The ZSF1 rat is currently used as a model to study DN, whereas 
no scientific study on DR performed in these animals has been reported to date. In this study, 
we extensively investigated whether the ZSF1 rat could represent a suitable animal model to 
study the pathogenesis of DR. In order to assess the retinal vascular changes caused by 
diabetes, such as arteriolar tortuosity, obese and lean control ZSF1 rats were subjected to 
Heidelberg Retina Angiography (HRA) and additional histological analysis over a period of 
42 weeks. We further examined the potential combined effect of chronic diabetes, obesity 
and hypertension on vasculature of retinas isolated from 6 and 42 weeks old obese and lean 
control ZSF1 rats, by assessing vascular density, pericyte coverage and number of microglia 
on whole mounted retina. The thickness of the neural retinal layers was assessed by Optical 
Coherence Tomography (OCT) over a period of 35 weeks. However, no differences were 
detected between obese and lean ZSF1 rats.  
Despite the increase in vascular tortuosity, obese ZSF1 rats did not develop DR. The 
absence of a DR phenotype would suggest the existence of a protective gene expression 
profile in these rats. Consistently, deep sequencing analysis of mRNA isolated from retinas 
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of 6 and 42 weeks old obese and lean ZSF1 rats, revealed the upregulation of several genes 
with a potential protective function, i.e. Neuropeptide Y (Npy) and several crystallin genes, 
at 42 weeks. Whereas genes, previously described to drive vascular inflammation, such as 
Intercellular Adhesion Molecule 1 (Icam1) and Toll-like receptor 4 (Tlr4) were 
downregulated in retinas from obese rats 42 weeks of age. 
A deeper understanding on the role of Npy and the crystallin genes in the retina following 
stressful conditions such as diabetes could be beneficial for developing better tools to 






































In the clinic, arteriolar tortuosity is routinely used as a marker to predict pathological 
neovascularization and rapid DR progression [12]. Therefore, we assessed arteriolar 
tortuosity index in lean and obese ZSF1 rats over a period of 6 to 42 weeks of age.  As shown 
in figure 1, the tortuosity index significantly increased in obese rats compared to their lean 
controls at 18, 26, 34 and 42 weeks, but did not differ when comparing lean and obese ZSF1 
rats at 5 and 14 weeks of age.  Increase in weight and blood glucose levels was confirmed in 





















Besides vessel tortuosity, two characteristics of DR are pericyte dropout and 
pathological neovascularization. Specifically, pericyte dropout leads to capillary occlusions 
followed by hypoxia [13, 14]. In the initial phase, blood vessels retract due to vessel 
instability caused by the loss of pericytes [15]. This leads to hypoxic areas, which in turn 
increases the expression of HIF-1 and subsequent VEGFA, resulting in pathological 
neovascularisation [16, 17]. Remarkably, deep and superficial vascular density and pericyte 
coverage did not differ between lean and obese animals at 6 and 42 weeks of age, but also 
there was no time-induced difference in obese and lean control ZSF1 rats at 42 weeks 
compared to those at 6 weeks (figure 2B-C). These results suggest that the vascular density 




Figure 1. Arteriolar tortuosity is increased in ZSF1 rats over time 
Arteriolar tortuosity index of the retinal vasculature from lean and obese ZSF1 rats, between 5 and 42 weeks 
old. Tortuosity index of the retinal arteries was increased in obese as compared to leans ZSF1 rat retinas of 18, 
26, 34 and 42 weeks of age. No difference in arteriolar tortuosity was detected in rats of 5 and 14 weeks of age. 












































Figure 2. Retinal vascular density and pericyte coverage are not affected by diabetes 
or age. 
Vascular density and pericyte coverage of retinal vasculature from 6 and 42 weeks old lean and obese ZSF1 
rats. (A) IB4 (green), NG2 (red) and a merge of signal of both the deep and superficial retinal vascular plexus. 
Scale = 50 µm. (B) Quantification of vascular density of the deep and superficial plexus shown in percentage 
of IB4 signal of the total area (n = 6-7 per data point). (C) Quantification of pericyte coverage of the deep and 
superficial plexus shown as ration of the NG2 and IB4 positive areas (n= 5-7 per data point). All values are 
mean +/- SD. 
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The activation of several signalling pathways during DR results in increased 
inflammation [4]. Microglia constitute the resident immune cells of the central nervous 
system [18] and they seem to play an important role during DR progression [19-21]. The 
number of Iba1-stained microglia was significantly higher in the retinas of both lean and 
obese ZSF1 rats at 42 weeks as compared to lean and obese ZSF1 rat at 6 weeks (figure 3A-
B), which is in line with an age-dependent increase [21]. However, the number of microglia 
did not differ between lean and obese ZSF1 either at 6 and 42 weeks of age (figure 3B), 



































Figure 3. The number of microglia is affected by age, but not diabetes. 
Number of microglia located in the retinas from 6 and 42 weeks old lean and obese ZSF1 rats. (A) IB4 (green) 
and Iba1 (cyan) and merge signal of the deep retinal vascular plexus. Scale = 50 µm. (B) Quantification of 
microglia number counted in the intermediate and deep vascular plexus (n = 5-7 per data point). All values are 
mean +/- SD, ****P<0,0001. 
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Next, we determined whether obese ZSF1 rats showed any changes in the morphology 
of their retinal vascular network, stained with IB4, as compared to their lean controls. An 
illustration of junctions, segments, loops and branches is reported in Supplementary figure 
2. In the deep retinal vascular plexus, the number of junctions, segments, loops and branches 
were significantly decreased in 42 weeks old lean and obese rats as compared to the 6 weeks 
old lean and obese ZSF1 rats, respectively (figure 4A-D; Deep). Also, in the superficial 
vascular plexus, the number of junctions, segments and branches were significantly 
decreased in the 42 weeks old obese ZSF1 rats compared 6 weeks old obese ZSF1 rats (figure 
4A, B, D; Superficial). No significant difference was found in the number of loops in the 
superficial plexus between the groups (figure 4C; Superficial). Finally, no significant 
difference was found in the number of junctions, segments, branches and loops in the 
superficial and deep plexus of retinal vasculature between lean and obese ZSF1 rats at 6 and 
42 weeks respectively. Overall, these results indicate that the vascular morphology in the 
retina is affected by age, but not by diabetes in both deep and superficial plexus. Functional 
analysis, i.e. OCT scan, of the retina was also performed. As shown in Supplementary figure 





































































Figure 4. The morphology of the vasculature is affected by age, but not diabetes. 
Quantification of vascular network morphology of the vascular deep and superficial plexus of retinas from 6 
and 42 weeks old lean and obsess ZSF1 rats. Number of junction (A), segments (B), loops (C) and branches (D) 
in the deep and superficial retinal vascular plexus (n = 5-7 per data point). All values are mean +/- SD, *P<0.05; 
**P<0.01; ***P<0.001; ****P<0,0001. 
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To identify genes able to prevent the onset of DR in obese ZSF1 rat, we performed 
sequencing of mRNA of retinas from 6 and 42 weeks old lean and obese, ZSF1 rats. Principal 
Component Analysis (PCA) resulted in a clear separation of lean from obese ZSF1 rats 
(figure 5). Although less pronounced, a separation based on age could be also distinguished 
within the lean and obese groups, i.e. 6 versus 42 weeks old lean and 6 versus 42 weeks old 




































Figure 5. Principal component analysis. 
Principal component analysis (PCA) plot based on the first two (PC1-PC2) components of mRNA from retinas 
from 6 and 42 weeks old lean and obese ZSF1 rats. 
Figure 6. Venn diagram. 
Venn diagram showing overlap between the differentially expressed genes (DEG) found in different 
comparisons, i.e. by age (Lean 6 vs Lean 42, purple and Obese 6 vs Obese 42, gray) and diabetes and metabolic 
syndrome (Lean 6 vs Obese 6, green and Lean 42 vs Obese 42, blue). The cut-offs for the DEGs were set to a 
Fold Change < or > 1,5 and FDR < 0,05. The numbers in the circle depict the number of DEGs found for that 
specific condition: i.e. in the bottom circle 51 DEGs are found in both Lean 6 vs Lean 42 and Lean 42 vs Obese 
42. 
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We performed statistical analysis on all genes expressed between the different groups. 
A gene was considered to be expressed when at least 5 reads were found aligned in at least 
all samples of one of the groups. In figure 6, we report the differential expressed genes 
(DEGs) found for all the comparisons. Changes in the expression of a total of 911 protein 
coding genes were identified (FC >1.5 False Discovery Rate (FDR)<0.05). A large majority 
of the DEGs identified per comparison was unique to that specific comparison, i.e. the DEGs 
were not significantly regulated in the other comparisons. Ingenuity Pathway Analysis (IPA) 
analysis showed the differently regulated pathways within the 4 comparisons: lean vs obese 
6 weeks old, lean vs obese 42 weeks old, lean 6 vs lean 42 weeks old, obese 6 vs obese 42 
weeks old (Supplementary table 1 to 4). Noteworthy, the leptin signalling pathway appeared 
to be differently regulated in the obese 6 and obese 42 weeks old (Supplementary table 4), 
confirming the metabolic phenotype affecting old obese ZSF1 rats (Supplements, table 4).  
Among genes only upregulated in the retinas from 42 weeks old ZSF1, we found 
Versican (Vcan), Forkhead Box D1 (Foxd1), MHC Class I Polypeptide-Related Sequence B 
(Micb) and Npy, whereas Cxadrl1, as Immunoglobulin Superfamily Member 11 (IGSF11), 
and Mal-like (Mall) were downregulated (Figure 7).  Remarkably, among the top regulated 
genes in retina from 6 vs 42 weeks old obese ZSF1, were several members of the crystallin 
gene family (Figure 8). Among them, Crybb3, Cryba2, Crygc, Crygb, Crygf, Crybb2, 
Cryba1, Cryba4, Crygs, were upregulated in obese 42 as compared to obese 6 weeks old. 
However, Crybb3, Cryba2, Crygc, Crygb, Crygf, Cryba1 were only upregulated in obese 42, 
indicating that their expression was likely affected by diabetes and metabolic diseases. On 
the other hand, Icam1 and Trl4, both known to play a determinant role during vascular 




















Figure 7. Heat map showing upregulation of several genes 
Heat map displaying fold changes of the differential expressed genes. The colors are ranging from red (-1 <= 












































Figure 8. Heat map showing upregulation of crystallin gene family 
Heat map displaying fold changes of the differential expressed crystallin (Crys) genes. The colors are ranging 
from blue (-2 <= log2 Fold Change (FC)) to green (FC ~ 0) to yellow (FC >= 2). 
Figure 9. Heat map showing upregulation of indicated genes 
Heat map displaying fold changes for indicated genes. The colors are ranging from white (-1 <= log2 Fold 




The ZSF1 rat, despite being obese, hypertensive, diabetic and hyperlipidemic, did not 
present any clear vascular defects in their retinas that could be attributed to progressive DR. 
Although vascular tortuosity increased in the diabetic rats over time, vascular density and 
pericyte coverage did not differ between diabetic and non-diabetic rats of 6 and 42 weeks of 
age. Microglia number and vascular network morphology differed in aged rats, but were 
unaffected by diabetes. Thickness of neural retina layers were also assessed by OCT scan, 
however no differences were found at the different analysed time points, in lean and obese 
rats. Absence of damage in the retinas from diabetic aged ZSF1 rats offered us the existing 
opportunity to investigate on possible molecular mechanisms that would prevent these 
animals from developing DR. We, therefore, performed mRNA sequencing in order to 
identify genes differentially expressed in retina isolated from lean and obese ZSF1 rats 6 and 
42 weeks of age with a possible protective role against DR. 
The RNA sequencing revealed that 85 genes were upregulated in the retinas from 42 
weeks old when compared to their lean control ZSF1 rats. Among the regulated genes, we 
found genes known to play a role in angiogenesis, inflammation, cellular stress and death. 
We found that genes involved in the process of angiogenesis, i.e. VCAN and Foxd1, were 
upregulated. In addition, the expression of the Micb gene, whose increase has been associated 
with degeneration of retinal ganglionic cells (RGC) and development of glaucoma [22], was 
upregulated in retinas from 42 weeks old ZSF1 rats. On the other hand, Cxadrl1, important 
for excitatory synaptic localization and plasticity, and Mall, encoding a component of raft 
mediated trafficking in endothelial cells, were both downregulated.  Although changes in 
expression of the above mentioned genes, together with increased vascular tortuosity, would 
suggest that an initial vascular and neuronal damage of the retinas in ZSF1 rats 42 weeks of 
age is occurring, we also found that several genes with a potential protective function, i.e. 
Npy and several crystallin genes, were significantly upregulated in retinas from 42 weeks old 
ZSF1 rats. Conversely, genes involved in vascular inflammation, like Icam1 and Trl4 [23, 
24], were downregulated in in retinas from 42 weeks old ZSF1 rats. 
Npy was first isolated in 1982 and is highly conserved between species [25]. In the 
retina, Npy seems to be required during development being expressed in different cell types 
[26]. Specifically, the neuroprotective role of Npy against excitotoxicity has been largely 
documented [27-29]. As such, Npy was shown to reduce the [Ca2+]i increase in rat neurons 
preventing their death [30]. The activation of several Npy receptors has been reported to 
protect retinal cells from necrosis or glutamate induced cell death [31].  Npy and its receptors 
are expressed in retinal endothelial cells, likely playing a role in retinal related vascular 
diseases [30]. In support of this, few studies have shown that Leucine to Proline 
polymorphism in the Npy gene was related to an increased predisposition to develop diabetic 
retinopathy in type 2 diabetic patients [32-34]. However, results on the role of Npy in 
oxygen-induced retinopathy model have been controversial. Whereas two studies [33, 35] 
suggested a positive role for Npy in the progression of neovascularization during DR, Schmid 
and collaborators [36] reported a decreased expression level of Npy in a similar model. 
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Therefore, further research is still needed to clarify the exact contribution of Npy in retinal 
vascular diseases. 
Several crystalline genes were also found to be upregulated in retinas of obese ZSF1 
when compared to lean 42 weeks of age. The crystallin genes were first described to encode 
structural proteins of the lens [37], but they are also expressed in other tissues and organs 
such as the retina [38], heart [39] and skeletal muscle [40]. The crystallins are divided in two 
families: the α-crystallin belonging to the small heat shock proteins (sHSP) and the β- and γ-
crystallins forming the β/γ superfamily.  Besides their function in lens transparency and 
reflex index, the α-crystallins are induced in response to stress and injury, displaying 
molecular chaperone and anti-apoptotic activity [41]. The β/γ crystallins regulate vascular 
remodelling during eye development and RCG axon regeneration [42]. Crystallin gene 
expression is altered upon DR [38], but their exact function during this process remains 
controversial. Although few studies have suggested a protective role of αB-crystallin genes 
against pathological neovascularization of the retina during diabetes , one study reported that 
delivery by intravitreous injection of recombinant adenovirus expressing αA-crystallin 
prevented vascular leakage and decreased pericyte loss in STZ-induced mouse model of 
diabetes [43-46]. The majority of those studies, however, investigated the role of α-crystallin 
genes during DR, whereas little is still known on the role of β/γ crystallins. From our RNA 
sequencing analysis, it emerges that diabetes and the metabolic syndrome induce the 
expression of crystallin β (i.e. Crybb3, Cryba2, Cryba1) and γ (i.e. Crygc, Crygb, Crygf) in 
the retina, whereas we did not observe any significant effect on α crystallins. 
Noteworthy, β and γ crystallin genes are upregulated in the retina of Nuc1 mutant rats 
as compared to wild type littermates [47]. Nuc1 mutants are characterized by a spontaneous 
mutation that affects neuronal and vascular remodelling and retinal function [48].  In 
particular, astrocytes at the vascular front seem to express β and γ crystallins together with 
VEGF. Moreover, in human persistent fetal vasculature (PFV) disease, in which the hyaloid 
vasculature does not regress normally, astrocytes expressed β and γ crystallins [47], 
suggesting a role for those crystallins in vascular stabilization in the eye. Besides being 
vasculoprotective, β/γ crystallins may also modulate axon regeneration [49]. Β/γ crystallins 
induce ciliary neurotrophic factor (CNTF) and brain derived neurotrophic factor (BDNF) 
both in vitro and in vivo [49]. In particular Crybb2 is secreted by cultured retinas during axon 
regeneration, and induces axon elongation in cultured RCG axons [42]. In conclusion, β/γ 
crystallin genes, which are upregulated in the retinas of 42 weeks old obese ZSF1 rats, might 
play a role in vascular stabilization and neuronal survival, preventing ZSF1 rats from 
developing DR. 
Vascular inflammation and leukostasis are early events in diabetic retinopathy with 
serious functional consequences. During DR leukocytes adhere to endothelial cells, causing 
vascular occlusion, macrophage accumulation and vascular tissue damage[50]. Several are 
the genes involved in these processes. Among them, Tumor Necrosis Factor α (Tnfα) 
modulates endothelial cell permeability and adhesion molecule expression [51]. Also, the 
expression of CD11a, CD11b, and CD18 integrins was shown to be increased on the surface 
of neutrophils from diabetic rats [50]. Proteins such as, Tnfα, NF-kB are Trl4 have been 
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extensively shown to regulate the inflammatory response [23].  Finally, Icam1 inhibition was 
reported to prevent diabetic retinal leukostasis and blood-retinal barrier breakdown [24]. 
Therefore, we assessed the expression of all these vascular inflammation markers and to our 
surprise we found that Icam1 and Trl4 were downregulated in in retinas from 42 weeks old 
ZSF1 rats, likely contributing to the protective mechanisms by reducing leukostasis and 
inflammation. 
Although the diabetic, hypertensive, obese and hyperlipidemic ZSF1 rat does not 
develop overt DR, it represents a useful model to identify new molecular signalling pathways 
beneficial to prevent the onset of DR. Remarkably, RNA sequencing analysis led us to 
identify Npy, β/γ crystalline, Icam1 and Trl4 genes that are differently expressed in lean and 
obese ZSF1 rats and could play a role in protecting old obese ZSF1 rats from developing DR. 
The roles that Npy and β/γ crystallins play in vascular remodelling and axon regeneration, 
and that Icam1 and Trl4 play in vascular inflammation, make them interesting candidates for 
new studies to target a complex ocular disease such as DR. Further characterization of the 
molecular mechanisms regulated by β/γ crystallins and Npy, Icam1 and Trl4, whose 
activation might be protective against DR, could possibly help us to design novel and more 






























All animal procedures conformed to the relevant guidelines and regulations of, and were 
approved by, the Animal Welfare Committee of the KU Leuven University. Male obese 
ZSF1 rats (ZSF1-LeprfaLeprcp/Crl) (Charles River Inc.) were used in this study. Male lean, 
non-diabetic, non-obese, but hypertensive ZSF1 rats were used as control. Rats were 
sacrificed at 6 and 42 weeks of age. The weight of each overnight fasting rat was recorded. 
Diabetes was confirmed after blood collection from rat tails at different time points (18, 22 
and 42 weeks) and glucose levels were determined with an automated glucose analyzer 
device (Glucometer, Menarini Diagnostics). 
 
• Heidelberg Retinal Angiography 
Rats were anesthetized by intraperitoneal injection of ketamine (Ketalar, 10 mg/mL) at 
a dose of 6.0 mg/kg and medetomidine hydrochloride (Domitor, 1.0 mg/mL) at a dose of 0.4 
mg/kg. Rats were injected intraperitoneally with 1 mL fluorescein sodium salt (Sigma, 
F6377-100G) 10% solution in saline. After the experiment, rats were awaken by 
intraperitoneal injection of atipamezole hydrochloride (Antisedan, 5 mg/ml) at a dose of 0.5 
mg/kg. Images were taken using a Heidelberg Retina Angiograph 2 (HRA2) (Heidelberg 
Engineering GmbH) according to the manufacturer’s recommendations. Tortuosity index 
was calculated from these photographs using the ImageJ software as previously described 
[52]. 
 
• Retina Isolation and Immunofluorescence 
Retina isolation and staining were carried out as previously described [53]. Blood 
vessels were stained with 20 µg/mL Isolectin GS-IB4 (IB4) (I21411, Thermo Fisher). 
Pericytes were stained with 5 µg/mL primary antibody Mouse anti-NG2 (Cat. No. NG2 37-
2700 Invitrogen) and microglia were stained with 2 µg/mL primary polyclonal antibody 
Rabbit anti-Iba1 (019_19741, Wako Laboratory Chemicals). 1:100 Goat anti-Mouse Alexa 
568 (A11031, Molecular Probes) and 1:100 Donkey anti-Rabbit Alexa 647 (A31573, 
Invitrogen) were used as secondary antibodies. Photos were taken using a Leica DFC350 
FX digital camera or Leica TCS SPE confocal.  
The images were processed and analyzed in ImageJ. The superficial and deep vascular 
plexus were separated based on the IB4 images. All analyses were performed on 20X 
magnification images with ImageJ Angiogenesis Analyzer. This tool allows detailed 
quantification of several vasculature structures, such as number of junctions, segments, loops 
and branches as shown in Supplementary Figure 2. Junctions were defined as meeting points 
of segments and/or branches. Segments were described as elements between two junctions 
and branches are elements between a junction and extremity. Loops were defined as areas 
enclosed by segments [54]. The percentage of IB4 positive areas was evaluated to determine 
vascular density. The percentage of NG2 positive areas was measured and the ratio of IB4 
and NG2 positive areas was calculated to determine pericyte coverage. For area calculations, 
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the images were quantified by ImageJ Area Fraction analysis. Microglia were quantified by 
ImageJ Cell Counter analysis.  
 
• Optical Coherence Tomography 
To assess thickness of the retinal layers and retinal morphology, a spectral domain 
optical coherence tomography (SD-OCT) system (Envisu R2210, Bioptigen, Morrisville, 
NC, USA) was used. To evaluate retinal morphology and neural retinal thickness an 
InVivoVue Diver 2.2 software (Bioptigen) was used as previously described in [55]. 
 
• RNA isolation and integrity 
RNA was isolated from the ZSF1 retinas using the mirVana™ miRNA Isolation Kit 
(Cat. No 1560, Ambion) according to the mirVana™ miRNA Isolation kit protocol. In a 20 
µL reaction volume, 1 µg RNA per sample was reverse transcribed into cDNA via the 
miScript II RT Kit (Cat. No. 218160, Qiagen), according to the manufacturer’s instructions 
using the 5x miScript HiFlex Buffer.  
The integrity of the RNA from each sample was scored on the Agilent 2100 Bioanalyzer 
(Agilent) by using an Expert Eukaryote Total RNA Pico chip according manufacturer’s 
protocol. Samples that had an RNA Integrity Number (RIN) value of over 6 were 
subsequently used for mRNA sequence library generation. 
 
• mRNA sequencing library generation 
The mRNA sequencing library was generated using TruSeq mRNA sample preparation 
kit (Illumina) according to manufacturer’s protocol. In short, mRNA was enriched using 
magnetic beads coated with poly-dT, followed by fragmentation. The fragmented mRNA- 
enriched samples were subjected to cDNA synthesis by reverse transcriptase, followed by 
dA-tailing and ligation of specific double-stranded bar-coded adapters. Subsequently, a 15 
cycles library amplification was performed and after clean-up, the sizes of the libraries were 
determined on an Agilent 2100 Bioanalyzer (Agilent) via an DNA 1000 chip according 
manufacturer’s protocol. Pooled libraries consisting of equal molar samples were sequenced 
on a high-output 75bp single read on the NextSeq500 (Illumina). 
 
• Total RNA analysis pipeline 
The analyses of sequencing datasets were performed as earlier described [56]. In short, 
reads were aligned to the rat rn6 reference genome using TopHat [43] and exonic reads were 
summed per transcript and transcripts were referred to as being expressed when at least five 








• Pathway analysis 
The differentially transcribed genes for the obese, i.e. 6 and 42 weeks, or lean, i.e. 6 and 
42 weeks, ZSF1 rats were investigated for over-represented pathways. We used normalized 
count reads, i.e. counts per million and log2 transformed, and performed a pathway 
enrichment analysis with Ingenuity pathway analysis (IPA) software. 
 
• Statistics 
Statistical analysis was performed by using GraphPad Prism 6. Statistical differences 
were examined by applying one and two-way analysis of variance tests (ANOVAs) followed 
by Tukey’s Multiple Comparison Test. A p value of less than 0.05 (P < 0.05) was considered 
statistically significant. Data are presented as the mean ± standard deviation (SD) or ± 
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Supplementary Figure 1 Body weight and glucose level measured in lean and obese ZSF1 83	
























































Supplementary Figure 1 Body weight and glucose level measured in lean and obese ZSF1 83	




























Supplementary Figure 2 Example of vascular network analysed by Angiogenesis Analyzer 110	
(A) and map (B) including junctions, segments, loops and branches. Scale = 50µm. Junctions 111	
(J) are indicated as dark blue circles and are the meeting point of several segments. Segments 112	
(S) are indicated in fuchsia and are vessels between two junctions. Loops (L) are indicated in 113	
light blue and are structures enclosed by segments. Branches (B) are vessels on segments that 114	









































Supplementary Figure 1.  
Body weight and glucose level measured in lean and obese ZSF1 rats at 18,22 and 42 weeks. All values are 
mean+- SEM, ****p<0.05. 
Supplementary Figure 2.  
Example of vascular network analyzed by Angiogenesis Analyzer (A) and map (B) including junctions, 
segments, loops and branches. Scale bar = 50 µm. Junctions (J) are indicated as dark blue circles and are the 
meeting point of several segments. Segments (S) are indicated in fuchsia and are vessels between two junctions. 
Loops (L) are indicated in light blue and are structures enclosed by segments. Branches (B) are vessels on 











































Supplementary Figure 3 Spectral domain optical coherence tomography (SD-OCT) 119	
analysis performed in lean and obese ZSF1 rats. (A) Representative SD-OCT pictures show 120	
no difference in morphology of the neural retina in Lean and Obese rats 35 weeks old. RNFL, 121	
retinal nerve fiber layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer 122	
plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium. Scale bar: 100 123	
µm; (B) Analysis of SD-OCT images revealed a similar thickness of the neural retina in Lean 124	





















Supplementary Figure 3.  
Spectral domain optical coherence tomography (SD-OCT) analysis performed in lean and obese ZSF1 rats. (A) 
Representative SD-OCT pictures show no difference in morphology of the neural retina in Lean and Obese rats 
35 weeks old. RNFL, retinal nerve fiber layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer 
plexiform layer; ONL, outer nuclear layer; RPE, retinal pigmented epithelium. Scale bar = 100 µm. (B) Analysis 
of SD-OCT images revealed a similar thickness of the neural retina in Lean and Obese rats at 20, 24 and 35 
weeks of age, respectively. 
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Supplementary Table 2.  
IPA revealed the top 5 canonical pathways expressed in retina isolated from Lean vs Obese 42 weeks old. 
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Supplementary Table 3.  
IPA revealed the top 5 canonical pathways expressed in retina isolated from Lean 6 vs Lean 42 weeks old. 
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Chapter 3: MicroRNA expression profile in diabetic patients 
































































Diabetic retinopathy (DR) is a leading cause of blindness worldwide. In diabetic 
patients, hyperglycemia can trigger major neurovascular complications within the eye, 
therefore resulting in pathological neovascularization and inflammation. Intravitreal 
injection of anti-VEGF is currently used in the clinic for proliferative DR, but it only shows 
partial efficiency. MicroRNAs are short non-coding RNAs that repress the expression of 
their target genes. These molecules are involved in a plethora of pathophysiological 
processes, including many ocular diseases. In the present study, we investigated the 
expression profile of a series of angiogenesis and inflammation related microRNAs by qRT-
PCR in the vitreous humors of diabetic patients, and in the retinas isolated from Akimba 
mice. First, we discussed the microRNA expression profile from vitreous humor samples of 
diabetic patients and compared it to existing literature. In a second time, we performed the 
same comparison with the microRNA expression profile from Akimba mice. This strategy 
led us to identify specific microRNA expression patterns. Overlap of human and mouse 
results highlighted 5 promising microRNAs for future investigations: miR-142-3p, miR-
146b-5p, miR-152-3p, miR-199a-3p and miR-320a. A characterization of the potential 
functional role of these microRNAs in angiogenesis and inflammation during DR will 



























Diabetes Mellitus (DM) is one of the world’s fastest growing chronic disease, affecting 
463 million individuals in 2019 and excepted to affect 578 million by 2030 [1]. Diabetes can 
lead to complications in many organs and systems such as the heart, the kidney and the 
nervous system, increasing the overall risk of premature death [2]. Diabetic retinopathy (DR) 
is a major complication of diabetes that affects the eye and leads to vision impairment and 
loss. DR affects 35,4% of diabetic patients and is the fifth leading cause of blindness 
worldwide [3]. With increasing prevalence of diabetes over years, DR incidence is expected 
to increase. 
DR is a neurovascular pathology triggered by hyperglycemia, affecting different cell-
type of the retina and involving several biochemical modifications [4]. It can be classified as 
non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR) and 
macular edema (ME). Specifically, PDR affects 7,2% of diabetic patients and is characterized 
by retinal neovascularization and inflammation, due to microglia activation, among other 
inflammatory cells [3, 5, 6]. Different animal models of DR are available, such as the 
streptozotocin (STZ)-induced models, the db/db mice (spontaneous mutation in the leptin 
receptor, leading to abnormal phenotypes in metabolic, reproductive and immune systems) 
and the Akimba mouse model. This latest model exhibits VEGF overexpression together 
with diabetic background, being thus a model of proliferative DR. However, all these models 
have their limitations [7, 8]. More recently, it was established that the ZSF1 rat model, despite 
showing precursor signs of DR, was protected from further progression of the disease, 
making thus this model a tool for studying resistance to DR development [9]. Anti-VEGF 
(Vascular Endothelium Growth Factor) therapy has emerged as a potential therapy for the 
treatment of PDR, overtaking classical laser photocoagulation [10]. In a randomized clinical 
trial, 46% of patients administrated with ranibizumab, a VEGF inhibitor, experienced 
improved vision [11]. However, despite showing a higher efficiency than laser therapy, anti-
VEGF therapy is not able to restore vision in DR patients. Therefore, the development of 
new therapeutic tools is urgently needed. 
Since their discovery in 1993 in C.elegans [12], microRNAs (also called miRNAs or 
miRs) have gain a large interest by the scientific community. Several studies have already 
focused on the potential role of microRNAs as biomarkers or targets for DR [13, 14]. Most 
of these studies considered serum or plasma circulating microRNAs, only a few investigated 
vitreous humors microRNAs. Unfortunately, the overlap of highlighted microRNAs in these 
studies remains poor. In addition, only a few studies addressed the question of a functional 
role of a specific microRNA in DR progression by modulating its expression in vivo.  
In the present study, we determined an expression profile pattern of angiogenic and 
inflammatory microRNAs in the vitreous of diabetic patients and compared it to previous 
similar studies. We also determined for the first time the expression profile of these 
angiogenic and inflammatory microRNAs in the Akimba mouse, a model of advanced 
proliferative DR. We highlighted 5 specific microRNAs whose expression were dysregulated 
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both in the Akimba mouse and in the vitreous humor of diabetic patients. Thus, we have 
identified a set of microRNAs that may have a regulatory function in DR. 
 
Material and Methods 
 
• Human vitreous humors 
The vitreous humor is a clear, colorless fluid that fills the space between the lens and the 
retina. It is made of 99% of water, the rest being mainly type II and type IX collagen fibers, 
hyaluronic acid, soluble proteins and hyalocytes. The vitreous helps to hold the spherical 
shape of the eye and helps to keep the retina in the posterior part of the eye. For a number of 
issues such as retinal detachment or vitreous hemorrhage, ophthalmologists can proceed to 
the removal of a part of the vitreous during a procedure called a vitrectomy. 
Vitreous humors from healthy control (i.e. non-diabetic) and diabetic patients were 
collected during vitrectomy needed for a medical purpose. After collection, fresh and 
undiluted samples were centrifuged to eliminate any circulating cells and then kept at – 80 
degrees until RNA isolation. Nine vitreous humors from healthy control patients as well as 
4 vitreous humors from diabetic patients were collected during a 3-year period of time.  
 
• Akimba mouse model 
The Akimba mouse model was generated and described by E.P. Rakoczy in 2010 [8]. 
This model was established to study the interaction of 2 main characteristics of diabetic 
retinopathy: hyperglycemia and VEGF overexpression. The Akimba mouse model was 
generated by crossing the Akita mouse with the Kimba mouse. Non-obese type-1 diabetic 
Akita mouse (also known as Mody mouse) exhibits a spontaneous mutation in the Insulin 2 
gene, leading to severe pancreatic b-cells dysfunction [15]. Transgenic Kimba mouse 
exhibits transient human VEGF165 photoreceptor-specific overexpression, leading to retinal 
neovascularization [16]. Akimba model retains both parental phenotypes, type-1 diabetic 
background and retinal neovascularization, being thus a suitable and attractive model for 
studying proliferative diabetic retinopathy.  
Akita, Kimba, Akimba and relative C57Bl6 Wild-Type (WT) mice were kindly provided 
by Oxurion. Three Akita mice, along with 5 Kimba, 5 Akimba and 5 WT mice were included 
in this study. Mice were scarified 3 months after birth, then eyes were enucleated and retinas 
of OD and OS were isolated and pooled together for each individual. Pooled retinas were 
then snap frozen in liquid nitrogen and kept at – 80 degrees until RNA isolation. 
 
• RNA extraction, Reverse transcription and qRT-PCR  
Vitreous humors were lysed in lysis buffer by vortexing, using the same quantity of 
vitreous humor (200 µL) for each patient. RNA was isolated from the lysate with miRNeasy 
serum/plasma kit (Qiagen) according to the manufacturer’s protocol. Reverse transcription 
was performed with Universal cDNA synthesis kit (Exiqon) according to the manufacturer’s 
instructions. qRT-PCR was performed with iQ SYBR green Supermix (Bio-Rad) according 
to the manufacturer’s instructions. MiRNA levels were assessed with miRCURY LNA 
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miRNA PCR Assay (Qiagen). All data were normalized to C. elegans miR-39 (Qiagen) 
expression as a spike-in control added to all samples prior to RNA isolation. 
Retinas were lysed with stainless steel beads (Qiagen) in lysis buffer with the 
TissueLyser LT (Qiagen). RNA was isolated from the lysate with mirVANA kit (Ambion) 
according to the manufacturer’s instructions. Reverse transcription was performed with 
miScript RT Kit II (Qiagen) using the same RNA input according to the manufacturer’s 
instructions. qRT-PCR was performed with iQ SYBR Green Supermix (Bio-Rad) according 
to the manufacturer’s protocol, with 10 ng cDNA as input. MiRNA levels were assessed with 
miRCURY LNA miRNA PCR Assay (Qiagen). All data were normalized to GAPDH and 
HPRT expression as housekeeping genes. 
 
• Selection of candidate microRNAs  
The 32/30 microRNAs tested by qRT-PCR in human/mouse samples were chosen from 
a literature research. This literature research was carried out in early 2017 on PubMed 
database and focused on determining a list of microRNAs with potential or known functions 
in angiogenic processes as well as in inflammatory processes. This biased approach for the 
selection of candidate microRNAs was intentionally used to highlight potential microRNAs 
implicated in inflammation and/or angiogenesis, the main biological features of proliferative 
diabetic retinopathy.  
 
• Data analysis 
All data underwent a statistical analysis using Prims7 software. All graphs are presented 
as mean +/- SEM. Mann-Whitney test or One-way ANOVA followed by post-hoc multiple 
comparisons tests were used to determine statistical significance. Statistical significance was 



















MicroRNA expression profile in the vitreous of diabetic patients 
In this study, we first analyzed the expression of 32 pre-selected microRNAs in the 
vitreous of diabetic patients by qRT-PCR (Fig. 1). Among these, 10 had a significant 
increased expression in diabetic patients when compared to healthy controls: miR-21-5p, 
miR-23b-3p, miR-29b-3p, miR-142-3p, miR-142-5p, miR-146b-5p, miR-152-5p, miR-








































































































































































































































** * * * *
*
Figure 1. MicroRNA expression profile in the vitreous of diabetic patients 
MicroRNA expression profile in the vitreous of diabetic patients compared to healthy vitreous. Diabetic vitreous 
results are presented as fold change to healthy vitreous (not shown on the graph). Results are presented as mean +- 
SEM. Mann Whitney test (n = 3-9 per experimental group) (* = p < 0.05).  
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MicroRNA expression profile in the retinas of Akimba and related parental mouse 
models 
We next analyzed the expression of the same 32 microRNAs in the retinas of Akita, 
Kimba and Akimba mice. MiR-329-3p and 429 were not detected in our samples. Out of the 
remaining 30 microRNAs whose expression was detected, 3 were dysregulated in Akita 
mice, 13 in Kimba mice and 20 in Akimba mice (Tab. 1). Akita mice exhibited increased 
expression of miR-21-5p and 221-3p, and decreased expression of miR-378a-3p. Kimba 
mice exhibited increased expression of miR-34a-5p, 142-3p, 146a-5p, 146b-5p, 195-5p and 
223-3p, while expressions of miR-18b-5p, 21-5p, 27b-3p, 92a-3p, 150-5p, 182-5p and 192-
5p were decreased. Akimba mice exhibited increased expression of miR-10b-5p, 31-5p, 34a-
5p, 126-3p, 142-3p, 146a-5p, 146b-5p, 152-3p, 184, 195-5p, 199a-3p, 210-5p, 221-3p, 223-
3p, 320a and 574-3p, while expressions of miR-92a-3p, 150-5p, 182-5p and 192-5p were 































miR-10b-5p 0 0 +
miR-18b-5p 0 - 0
miR-21-5p + - 0
miR-23b-3p 0 0 0
miR-27b-3p 0 - 0
miR-29b-3p 0 0 0
miR-31-5p 0 0 +
miR-34a-5p 0 + +
miR-92a-3p 0 - -
miR-126-3p 0 0 +
miR-142-3p 0 0 +
miR-142-5p 0 + 0
miR-146a-5p 0 + +
miR-146b-5p 0 + +
miR-150-5p 0 - -
miR-152-3p 0 0 +
miR-182-5p 0 - -
miR-184 0 0 +
miR-192-5p 0 - -
miR-195-5p 0 + +
miR-199a-3p 0 0 +
miR-200b-3p 0 0 0
miR-200c-3p 0 0 0
miR-205-5p 0 0 0
miR-210-5p 0 0 +
miR-221-3p + 0 +
miR-223-3p 0 + +
miR-320a 0 0 +
miR-378a-3p - 0 0
miR-574-3p 0 0 +
Table 1
Overview of microRNA
dysregulation in the retinas
of Akita, Kimba and Akimba
mice model
0 = no difference compared to
WT mice; + = upregulated
compared to WT mice; - =
downregulated compared to
WT mice.
Table 1. Overview of microRNA dysregulation in the retinas of Akita, Kimba and 
Akimba mice model 
0 = no significant difference compared to WT mice; + = upregulated compared to WT mice; - = downregulated 













































































































































































































































































Figure 2. MicroRNA expression profile in the retinas of Akita, Kimba and Akimba 
mice model 
MicroRNA expression profile in the retinas of Akita, Kimba and Akimba mice compared to WT mice. Akita, 
Kimba and Akimba results are presented as fold change to WT mice (not shown on the graph). Results are 
presented by mean +- SEM. One-way ANOVA + multiple comparison test (n = 3-5 per experimental group) 
(* = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001; **** = p ≤ 0.0001). 
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Overlap of overexpressed microRNAs in diabetic patients and Akimba mice 
The overlap of upregulated microRNAs in both human and mouse samples highlighted 
5 microRNAs whose expression was increased compared to control conditions. These 
microRNAs were miR-142-3p, miR-146b-5p, miR-152-3p, miR-199a-3p and miR-320a 

































Venn diagram showing overlap of upregulated microRNAs in the
vitreous of diabetic patients and the retinas of Akimba mice
Among the 32 microRNAs tested in the vitreous of diabetic patients and the
30 microRNAs tested in the retinas of Akimba mice, 5 microRNAs showed
a common overexpression in both models. These microRNAs are miR-142-






Figure 3. Venn diagram showing overlap of upregulated microRNAs in the vitreous 
of diabetic patients and the retinas of Akim  mice 
Among the 32 microRNAs tested in the vitreous of diabetic patients and the 30 microRNAs tested in the retinas 
of Akimba mice, 5 microRNAs showed a common overexpression in both models. These microRNAs are miR-




Vitreous humors of diabetic patients exhibit a specific microRNA expression 
profile  
In this study, we analyzed the expression profile of a set of microRNAs in the vitreous 
of diabetic patients. Human samples were initially collected in the context of a research not 
focusing on DR. Thus, we were only able to collect vitreous of diabetic patients and healthy 
control patients, but no vitreous of NPDR or PDR patients had been collected. Several studies 
have recently reported microRNAs expression profile in the vitreous of diabetic patients with 
or without diabetic retinopathy, all recently reviewed in [13] and [14]. Interestingly, our 
results show similarities with these previous studies but also major differences.  
MiR-21, previously described as a pro-angiogenic and pro-fibrotic microRNA, was 
upregulated in our samples of diabetic patients, in line with its vitreous expression in patients 
with a proliferative vitreoretinal disease patients [17]. Interestingly, miR-21 was also 
upregulated in the serum of PDR patients when compared to NPDR patients, making this 
microRNA a monitoring factor for detecting the progression of PDR from NPDR [18]. Thus, 
miR-21 appears to be a microRNA implicated in both primary onset and DR progression. 
Future studies will have to determine if a correlation between miR-21 quantity and DR 
progression can be observed. In a previous study, miR-29a and miR-320a were upregulated 
in PDR vitreous when compared to control (macular hole, MH) [19]. In the same study, miR-
320a was also upregulated in the serum of PDR patients, but not miR-29a. Similarly, our 
analysis revealed a similar increase of miR-320a and miR-29b, a close isomiR to miR-29a, 
in the vitreous of diabetic patients. While miR-142-3p was specifically expressed in the 
vitreous of PDR patients but not detected in the vitreous of MH control patients [19],  we 
detected miR-142-3p in both diabetic and control group, with a significantly higher 
expression in the diabetic group. In the same study, miR-142-5p was not detected in either 
control (macular hole) patients or PDR patients. Similarly, miR-152-5p was upregulated in 
our vitreous samples of diabetic patients, but was not in the other studies including both MH 
and PDR groups.  
In conclusion, our set of diabetic vitreous samples shows partial matches with what is 
known from the literature. However, we also highlighted specific features of miRNA 
expression that was not describe until now. In this way, we showed a specific overexpression 
of miR-23b-3p, miR-146b-5p, miR-152-5p and miR-378a-3p. To our knowledge, these 
microRNAs have never been described yet in a context of diabetic vitreous samples. Despite 
showing particular specificities, our set of samples failed to highlight some well-described 
microRNAs in DR such as miR-200b [20, 21]. 
Taken together our data suggest that the vitreous microRNA content of diabetic patients 
partially overlap the vitreous content of DR patients. However, all these data have to be 
considered with care due to methodological considerations and limitations. First, the 
procedure of vitreous collection is not always described, particularly the centrifugation step. 
Indeed, vitreous humor can content several circulating cell-types such as macrophages and 
red blood cells, in particular in hemorrhagic and inflammatory conditions. Thus, 
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centrifugation allows the elimination of cell pellets. The resulting microRNA expression 
profile that we obtained in this study is thus originating from exosomes or microvesicles, 
which are known to be carrier of microRNAs in different body fluid such as vitreous humor 
[22, 23]. Second, the method of detection used has to be taken in consideration. In most 
studies, microRNA expression profile was first obtained by microarray analysis than 
confirmed by qRT-PCR. Here, we assessed the microRNA composition by qRT-PCR, 
leading to possible biased results. Moreover, which one of the mature microRNA strand (5p 
or 3p) was used for a particular study is not always described by the authors. Finally, the type 
of control patients might interfere with the comparison of the different studies. Indeed, 
several clinical feature of control patients -sex, age and co-morbidities among other- could 
alter the expression profile. 
 
Retinas of Akimba mice exhibit a specific microRNA expression profile 
Out of the 32 microRNAs tested in human samples, only 30 were expressed in mouse 
samples: miR-329-3p and miR-429 were not detected in Akimba mice and parental strains. 
To our knowledge, this is the first time that a microRNAs expression profile is reported in 
the Akimba mouse model of PDR. 
Akimba mice show enhanced pro-inflammatory and pro-angiogenic characteristics such 
as activation of NLRP3 inflammasome and loss of blood-retinal barrier (BRB) [24, 25]. 
Thus, a large microRNA dysregulation in Akimba retinas was to be expected. Two of the 
most upregulated microRNAs were miR-146a-5p and miR-146b-5p, well-described for their 
regulatory functions in immune responses and angiogenesis [26]. These distinct microRNAs 
only differ by 2 nucleotides in the 3’ region and share identical seed sequence, and therefore 
share predicted downstream targets. Their overexpression is thus concomitant with the highly 
inflammatory environment encountered in Akimba retinas. At the functional level, 
intravitreal delivery of miR-146 successfully attenuates inflammatory phenotype in both 
SZT-induced diabetic rat model as well as in a model of Experimental Autoimmune Anterior 
Uveitis (EAAU), another common ocular inflammation disorder [27, 28]. Taken together, 
these data suggest a potential implication of both miR-146a-5p and miR-146b-5p in PDR. 
This should be further confirmed by intravitreal injection of miR-146 inhibitor and mimic in 
the Akimba model.  
In parallel to the 2 most upregulated microRNAs, the expression of miR-92a-3p and 
miR-182-5p is strongly decreased in the eyes of Akimba mice. MiR-92a-3p is a pro-
angiogenic mediator produced by endothelial cells (EC) and packed into extracellular 
vesicles. In a diabetic context, miR-92a-3p is elevated in high-density lipoprotein (HDP) 
fraction in reconstituted HDL-infused mice early after ischemia [29]. However, no 
description of this microRNA has been made in a DR context. It is thus surprising to observe 
that miR-92a-3p is downregulated in Kimba and Akimba mice while they show a strong 
neovascularization phenotype. This might be explained by the fact that miR-92a-3p is 
transcribed from the miR-17/92 cluster [30]. Further characterization of miR-92a-3p 
expression in Akimba samples should thus be accompanied by assessment of expression 
level of other microRNAs originating from the same cluster such as miR-17 or miR-20a. The 
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second most downregulated microRNA was miR-182-5p, with poorly described function. 
MiR-182 is overexpressed in diabetic nephropathy (DN) patients and is responsible for 
podocytes apoptosis, leading to an increased risk of DN [31]. It is also a key regulator of 
diabetic corneal nerve regeneration [32]. Implications of miR-182-5p in the diabetic eye 
might thus be related to apoptosis and regeneration, but requires further investigations. 
While Akimba mice retain both VEGF overexpression and diabetic status from parental 
strains, Akita strain only have a DM background. Thus, comparison of microRNAs 
dysregulation in diabetic patients and diabetic mice could be relevant. Only a poor overlap 
in microRNAs expression profile in Akita’s retinas and vitreous of diabetic patients is 
present. While miR-21-5p is overexpressed in both human and Akita mouse samples, miR-
378a-3p is downregulated in human and upregulated in mouse. MiR-221-3p overexpression 
is only observed in mouse and not in human. Even if miR-221-3p was not dysregulated in 
our set of human samples, this specific microRNA is overexpressed in the serum of PDR 
patients [33]. A positive correlation between miR-221 level and DR progression was 
observed. Thus, miR-221 concentration seems to increase both in NPDR and PDR compared 
to healthy patients. 
Despite showing strong inflammatory and angiogenic phenotypes, the Akimba mouse 
model may not be the most appropriate model for proliferative DR since it also shows severe 
accessibility limitations. Indeed, this mouse model is protected under a patent and its 
accessibility for academic research is very complicated. Moreover, breeding of Akimba mice 
is difficult, since crossing of parental strains results in a low number of viable pups (+- 10 % 
of viable pups). Altogether, these particularities make the Akimba mouse model poorly 
accessible. 
 
Promising targets for further proliferative DR investigations  
In order to define a specific set of angiogenic and/or inflammatory related microRNAs 
in PDNR, we merged the data in diabetic patients and Akimba mice. As such, miR-142-3p, 
miR-146b-5p, miR-152-3p, miR-199a-3p and miR-320a emerge as overlapping targets, and 
future studies will have to address their functional role in DR progression. To our knowledge, 
no studies have currently addressed the question of a functional role of these microRNAs in 
a PDR context. Local or systemic delivery of miR inhibitor and mimic in the Akimba model 
and parental strains as well as in other animal models of DR could therefore improve our 












Since their discovery, microRNAs appeared to be master regulators of numerous 
physiological and pathological processes. In the course of proliferative diabetic retinopathy, 
a vision-threatening ocular disease, many microRNAs show dysregulated expression profile. 
Among these microRNAs, some are of particular interest since their dysregulation is 
concomitantly observed in both animal models and human samples. Thus, further 
characterization of microRNAs expression profile could help in the diagnosis of PDR. Here, 
we investigated the expression profile of a large panel of microRNAs expressed in the 
vitreous of diabetic patients and in the retinas of Akimba mice. We also defined a set of 5 
specific microRNAs, namely miR-142-3p, miR-146b-5p, miR-152-3p, miR-199a-3p and 
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Chapter 4: Intravitreal injection of anti-miRs against 
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Age-related macular degeneration (AMD) is a worldwide leading cause of blindness 
affecting individuals over 50 years old. The most aggressive form, wet AMD, is 
characterized by choroidal neovascularization (CNV) and inflammation involving microglia 
recruitment. By using a laser-induced CNV mouse model, we provide evidence for a key role 
played by miR-142-3p during CNV formation. MiR-142-3p was overexpressed in murine 
CNV lesions and its pharmacological inhibition decreased vascular and microglia densities 
by 46% and 30%, respectively. Consistently, miR-142-3p overexpression with mimics 
resulted in an increase of 136% and 126% of blood vessels and microglia recruitment. 
Interestingly, miR-142-3p expression was linked to the activation state of mouse microglia 
cells as determined by morphological analysis (cell solidity) through a computational 
method. In vitro, miR-142-3p overexpression in human microglia cells (HMC3) modulated 
microglia activation, as shown by CD68 levels. Interestingly, miR142-3p modulation also 
regulated the production of VEGF-A, the main pro-angiogenic factor. Together, these data 
strongly support the unprecedented importance of miR-142-3p-dependent vascular-

































Globally, 2.2 billion people suffer of vision impairment or blindness [1]. Age-related 
macular degeneration (AMD) is the fourth leading cause of blindness worldwide [2], 
affecting 8.7 % of population. This percentage is expected to increase due to the ageing 
population [3]. Although less frequent than atrophic (or dry) AMD, neovascular (or wet) 
AMD represents the most vision-threatening form of the disease [4]. It is mainly 
characterized by choroidal neovascularization (CNV), the formation of abnormal blood 
vessels arising from the choroid and invading the subretinal space, leading to vision 
impairment [5]. This angiogenic process is associated with the recruitment and proliferation 
of inflammatory cells including neutrophils, macrophages and microglia [6, 7]. The latter 
cells are the main resident immune cells and contributors to the innate immunity within the 
central nervous system, including the retina. At the experimental level, rodent models of 
laser-induced CNV are the most broadly used for neovascular AMD pre-clinical research [7, 
8]. They recapitulate the angiogenic and inflammatory phases of the disease including 
microglia implication. Antibody-based anti-VEGF (Vascular Endothelium Growth Factor) 
therapy is still the golden standard for the management of neovascular AMD [9]. 
Unfortunately, around one fifth of neovascular AMD patients do not or poorly respond to 
anti-VEGF therapy [10]. Therefore, additional therapies are urgently required.  
MicroRNAs, also called miRs or miRNAs, are short non-coding RNA species of about 
20-24 nucleotides length, which act as post-transcriptional gene-expression regulators. A 
single mature microRNA can bind to several mRNAs and a single mRNA can be targeted by 
several miRNAs [11-13]. Many ocular diseases are regulated by short non-coding RNAs, 
and a growing body of literature related to miRNA complications in eye disorders is currently 
emerging [14, 15]. To date, several teams have focused on establishing microRNAs as 
potential AMD biomarkers in both human and mouse study [16, 17]. However, only a few 
of these studies addressed the question of a functional role of microRNAs in AMD [18]. 
Through their capacity to regulate biological processes such as angiogenesis and 
inflammation [19, 20], a functional contribution of miRNA in AMD is expected, but poorly 
documented. Hence, miRNA as therapeutic target for the treatment of AMD is an emerging 
concept for future drug design. 
In the present study, we searched for microRNAs with functional implication in CNV 
development. We first determined the expression profile of a set of angiogenesis and 
inflammation-related microRNAs in mouse CNV lesions. Inhibition and overexpression of 
miR-142-3p, one of the top dysregulated microRNAs, regulated both vascular and 
inflammatory phenotypes. Notably, microglia recruitment and activation were enhanced by 
miR-142-3p mimic and reduced by miR-142-3p inhibitor both in vitro and in vivo. Our work 
provides evidence that miR-142-3p is a functional mediator during CNV progression and 
acts as a microglia cell activator. MiR-142-3p is worth considering as a target for future 




Material and methods 
 
• Laser-induced choroidal neovascularization mouse model 
CNV was induced in mice by laser-mediated choroid burn as previously described [7]. 
Briefly, 6 to 8 weeks old C57Bl6 mice (all males) (Janvier, France) were anesthetized by 
intraperitoneal injection of a mixture of ketamine (50 mg/kg) and medetomidine (0.5 mg/kg). 
A few minutes before laser induction, pupils were dilated with Tropicol (Théa Pharma, 
France). Four laser burns per eye were performed with MicronIV instrument (Phoenix Lab, 
USA) leading to Bruch’s membrane local destruction and the subsequent choroidal 
neovascularization. Mice were than woken up by intraperitoneal administration of 
atipamezole (1mg/kg). Mice were sacrificed 5 (D5) or 7 days (D7) after laser induction by 
cervical dislocation. All in vivo experiments were approved by the local Animal Ethic 
Commission (File number 17-1986, “Commission d’éthique de l’utilisation des animaux de 
l’Université de Liège”). 
 
• Laser microdissection of the choroid 
Mice subjected or not to CNV induction were sacrificed at D5 or D7 post-laser burn (n 
= 5-10 per experimental group, 4 CNV lesions per eye). Eyes were enucleated, placed fresh 
in Tissue-Tek OCT medium (VWR, USA) and stored at -80 °C until section preparation and 
laser microdissection. The day of laser microdissection, eyes were placed on dry ice until 
cryosection (Cryostat Cryotome FSE, Thermo Scientific). Ten µm sections were performed 
and place on PEN-Frame slides (Leica, Germany). Regions of interest (ROIs) were 
microdissected with Leica Laser Microdissection LMD 7000 and directly collected in lysis 
buffer for subsequent RNA extraction. Samples were collected from 3 different ROIs: control 
choroid (from control mouse not subjected to CNV), CNV lesion (neovascular tissue from 
laser-induced mouse) and their corresponding adjacent choroid (healthy tissue next to CNV 
lesion from laser-induced mouse). For each ROI, microdissected tissues from the two eyes 
of a single mouse were pooled before RNA extraction.  
 
 
• Intravitreal injections and optical coherence tomography (OCT) 
To assess inhibition/overexpression of miR-142-3p, intravitreal injections of inhibitor 
(single stranded LNA-antimiR) or mimic (chemically modified double-stranded) were 
performed in mice, just after laser induction (D0, inhibitor conditions), or just after laser 
induction and 5 days later (D0 + D5, mimic conditions) (n = 11-15 per experimental group 
for flat-mounted choroids; n = 5-10 per experimental group for flat-mounted retinas). During 
general anesthesia, mouse eyes were locally anesthetized with Unicaïn 0.4% (Théa Pharma) 
before the injection, in the vitreous chamber, of a solution (2 µL) of inhibitor (1.83 mM) or 
mimic (10 µM). Negative control inhibitor and miR-142-3p inhibitor were purchased from 
Qiagen (miRCURY LNA miRNA Inhibitors, The Netherlands). Mimics (negative control 
and miR-142-3p mimic) were from Ambion (mirVana miRNA Mimics, USA). After 
intravitreal injection, eyes were covered with Trafloxal (Bausch + Lomb, Austria) to avoid 
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any infection and inflammation. Both eyes of a single mouse received the same treatment. 
Phenotypic alterations consequent to miR-142-3p modulation were assessed through optical 
coherence tomography (OCT) measurements by using the MicronIV instrument, through 
vascular and microglia stainings on flat-mounted choroids, and through microglia staining 
on flat-mounted retinas. OCT measurements are presented as (b-c)/c ratios, where b is the 
CNV lesion thickness and c the adjacent choroid thickness [7]. For miR-142-3p mimic 
conditions, FITC-dextran (FD2000S, Sigma, USA) tail vein injections were performed 3 
minutes before sacrifice.  
 
• RNA extraction, Reverse transcription and qRT-PCR  
Laser-captured choroids or cells were homogenized in lysis buffer by vortexing. For 
some qRT-PCR, whole retinas and choroids were lysed with ceramic beads (MagNA Lyser 
Green beads, Roche, Switzerland) in lysis buffer with tissue homogenizer (Precellys 
Evolution, Bertin, France). RNA was then extracted with miRNeasy Micro kit (laser-
captured choroids) (Qiagen) or with mirVana kit (all other experiments) (Ambion), according 
to the manufacturer’s protocols. Complementary DNA was synthesized with miScript RT 
Kit II (Qiagen) using the same RNA input according to the manufacturer’s instructions. 
mRNA levels of different targets and a set of microRNA levels were quantified by qRT-PCR 
using FastStart SYBR Green Master (Roche) and a LightCycler 96 instrument (Roche). 
MiRNA levels were assessed with miRCURY LNA miRNA PCR Assay (Qiagen). All data 
were normalized to GAPDH and snU6 expression as housekeeping genes. Primer sequences 


















Forward (f) and reverse (r) primer sequences for mouse (mmu) and human (hsa) target 
mRNAs. 
 
 5’ - sequence - 3’ 
mmu-GAPDH f: ggtggacctcatggcctaca 
r: ctctcttgctcagtgtccttgct 
mmu-uPA f: taaaatgctgtgtgctgcgg 
r: gcggccttcgatgttacaga 
mmu-hsa-snU6 f: cgcttcggcagcacatatac 
r: ttcacgaatttgcgtgtcat 
hsa-GAPDH f: acccactcctccacctttgac 
r: accctgttgctgtagccaaatt 
hsa-CD68 f: cagggaatgactgtcctcaca 
r: ctctgtaaccgtgggtgtca 
hsa-VEGFa f: cctccgaaaccatgaacttt 
r: atgattctgccctcctctt 
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• Western blotting  
Cells were lysed with 1X lysis buffer (9803, Cell Signaling, USA) containing protease 
and phosphatase inhibitors (Complete and Phos-STOP, Roche). Proteins (15 µg) were 
separated on acrylamide gels and transferred onto PVDF membranes. BCLAF1 proteins were 
detected by overnight incubation, at 4 °C, with recombinant anti-BTF antibody (1/10 000 
dilution) (Ab181240, Abcam, UK) followed by 1h incubation, at room temperature, with 
horseradish peroxidase-coupled secondary antibody (7074, Cell signaling) and enhanced 
chemiluminescent substrate (NEL1040001EA, PerkinElmer, USA) using a LAS4000 imager 
(Fujifilm). GAPDH (1/10 000, MAB 374, Millipore, USA) was used as a loading control. 
 
• Immunohistochemistry  
For mouse microglia immunostaining, eyes were enucleated and fixed in 
paraformaldehyde 4% for 1 hour. Subsequently, retinas and choroids were isolated, 
permeabilized, blocked and incubated with anti-Iba1 antibody (1/1000 dilution) (Abcam 
Ab178846) overnight, at room temperature. The next day, samples were washed, incubated 
with secondary antibody (1/200 dilution) (goat anti-rabbit AlexaFluor 595, Invitrogen 
A11012, USA) for 2 hours and washed again. Retinas and choroids were flat-mounted with 
Fluoromount-G (SouthernBiotech, The Netherlands) on glass-slides for microscopy 
imaging. 
For mouse vascular immunostaining, eyes were enucleated and fixed in ethanol 70 % 
for 1 hour. Subsequently, choroids were isolated, permeabilized, blocked and incubated with 
anti-CD31 antibody (1/150 dilution) (Pharmingen 553370) overnight, at room temperature. 
The next day, samples were washed, incubated with secondary antibody (1/200 dilution) 
(goat anti-rat AlexaFluor 488, Invitrogen A11006) for 2 hours and washed again. Choroids 
were flat-mounted with Fluoromount-G (SouthernBiotech) on glass-slides for microscopy 
imaging. 
 
• Epifluorescence/confocal microscopy and image quantifications 
Flat-mounted Iba1/CD31 stained choroids were observed under an Olympus Vanox 
epifluorescence microscope (inhibitors conditions). Flat-mounted Iba1/FITC stained 
choroids were observed under a Leica Sp5 confocal microscope (mimics conditions) and Z-
stacks (z-path = 2.5 µm) were taken. Each CNV lesion was separately imaged and maximum 
intensity projections were performed for Iba1/FITC images. For each CNV lesion, the area 
occupied by the staining was calculated with Fiji software [21]. The mean area for a single 
eye was than calculated for each staining. The percentage of stained area within an eye, 
normalized to control condition, was used for subsequent statistical analysis to determine 
vascular and microglia densities. 
For cell solidity analysis, Z-stacks of flat-mounted Iba1 stained retinas were taken with 
a high-resolution confocal microscope (Zeiss LSM 880 with Airyscan), at the 20X 
magnification. Every CNV lesion was separately imaged, each image representing a 780 µm 
long square, englobing one CNV area and the surrounding tissue. After acquisition, images 
were first processed and then quantified. The processing procedure started by identifying 
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image background with morphological opening operations and subtracting it from the raw 
images. They were then thresholded using Otsu’s method and subjected to a median filter to 
reduce noise. First quantification steps consisted in detecting every objects of the image and 
discarding the ones which were too small/big to be an isolated cell or a small cell cluster. 
The bright center of the cells was then used to segment and isolate each cell. Remaining non-
cellular objects were discarded using shape and size filters. Finally, tridimensional solidity 
was measured for every cell. The mean cell solidity of all the CNV lesions area of a single 
eye was calculated and then used for subsequent data analysis. The solidity of an object is 
defined as the ratio of the volume of this object over its convex volume. The convex volume 
corresponds to the volume of the convex hull of the region, i.e. the smallest region that satisfy 
two conditions: (1) it is convex (2) it contains the original region. 
 
• Cell culture 
Human microglia HMC3 cells were purchased from ATCC (CRL-3304, USA) and 
cultured according to the manufacturer’s instructions. Cells were seeded in 6-well plate 
(2.105 cells per well) the day before transfection or stimulation. HMC3 were transfected with 
5 nM of miR-142-3p inhibitor/negative control inhibitor or with 5 nM miR-142-3p 
mimic/negative control mimic. Transfection was performed using INTERFERin reagent 
(Polyplus transfection) following manufacturer’s protocol. Cells were harvested 24-hour 
post-transfection to assess miR-142-3p, BCLAF1 transcript and VEGF-A levels, or 48-hour 
and 72-hour to assess CD68 and BCLAF1 protein levels, respectively. Alternatively, HMC3 
underwent pro-inflammatory stimulation by a 24 hours exposure to 10 ng/mL IFNg 
(Recombinant Human IFNg, Peprotech, USA) or to 0,1 µg/mL LPS (Lipopolysaccharides 
from Escherichia coli 0111:B4, Sigma, USA). 
 
• Data analysis 
All data and measurements underwent a statistical analysis using Prims7 software. All 
graphs are presented as mean +/- SEM. Mann-Whitney test or Kruskal-Wallis followed by 
post-hoc multiple comparisons tests were used to determine statistical significance. 















MiR-142-3p is overexpressed in a laser-induced CNV mouse model 
Laser microdissection was used to isolate three types of samples from mice subjected or 
not to laser-induced CNV: i) control choroid from control mice (not subjected to CNV 
induction), ii) CNV lesions, and iii) adjacent choroid (healthy choroid adjacent to CNV 
lesion) (Fig. 1A). In a pilot experiment, the expression profile of 15 angiogenesis and/or 
inflammation-related microRNAs were determined 7 days post-induction by qRT-PCR in 
the 3 regions of interest (Fig. 1B). Although probably not extensive enough, we focused our 
attention only on these 15 microRNAs i) because of limited RNA availability after laser 
microdissection and ii) because these microRNAs are reported angiogenesis and/or 
inflammation mediators. Among those microRNAs tested, only 4 were dysregulated: miR-
21-5p, miR-34a-5p and miR-142-3p increased whereas miR-574-3p decreased upon laser-
induction. To further confirm the overexpression of miR-142-3p in laser-induced CNV 
mouse, laser microdissection was repeated 7 days as well as 5 days post laser-induction. 
Interestingly, miR-142-3p increased in the CNV lesions, both at days 5 and 7 post laser 
induction (Fig. 1C), and correlated with the overexpression of uPA (urokinase plasminogen 
activator) used here as a CNV-disease marker [22] (Fig. 1D and Supp. 1). Taken together, 
these data suggest that miR-142-3p could act during CNV progression in the laser-induced 
























Figure 1. MiR-142-3p is overexpressed in a laser-induced CNV mouse model.  
A Cryosections of control mouse (untreated) and laser-induced mouse delineating the different regions of 
interest (ROI). These ROIs, namely control choroid (in blue), adjacent choroid (in green) and CNV lesion (in 
orange), were isolated by laser microdissection. Scale bar = 250 µm. B MicroRNA expression in CNV lesion 
and adjacent choroid compared to control choroid, 7 days after laser induction. Results of CNV lesion and 
adjacent choroid are expressed as fold change to control choroid. Results are presented as mean +- SEM. One-
way ANOVA followed by multiple comparisons test (n = 5 per experimental group). C&D Overexpression of 
miR-142-3p (C), and uPA (D), a CNV-disease marker, at day 5 (D5) and day 7 (D7). MiR-142-3p and uPA are 
specifically overexpressed in CNV lesion 5 and 7 days post laser induction. qRT-PCR results are presented as 
mean +- SEM. One-way ANOVA + multiple comparisons test (n = 10 for control choroid, n = 5 for adjacent 
choroid and CNV lesion D5, n = 10 for adjacent choroid and CNV lesion D7) (* = p ≤ 0.05; ** = p ≤ 0.01; *** 
= p ≤ 0.001 ) 
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Modulation of miR-142-3p expression alters neovascularization and inflammation 
in CNV mouse model 
Intravitreal injections of miR-142-3p inhibitor or mimic allowed us to evaluate the 
functional role of miR-142-3p during CNV progression in the laser-induced CNV mouse 
model. CNV lesion thickness, as assessed by OCT measurements, was lower in mice injected 
with miR-142-3p inhibitor when compared to control inhibitor (Fig. 2A) (p = 0.0149). This 
inhibitor reduced by 46 % the blood vessel density in CNV mouse (Fig. 2B, top panels) (p = 
0.0157). Concomitantly, microglia area, a major component of the innate immunity in the 
eye, was decreased by 30 % upon miR-142-3p inhibition (Fig. 2B, bottom panels) (p = 
0.0292). Therefore, miR-142-3p inhibition alleviates CNV progression by decreasing 
neovascularization and inflammation. Inversely, the overexpression of miR-142-3p through 
mimic injection slightly enhanced CNV lesion thickness (Fig. 3A) (p = 0.0407). It also 
increased the angiogenic response by 136 % (Fig. 3B, top panels) (p = 0.0233) and microglia 
cell recruitment by 126 % (Fig. 3B, bottom panels) (p = 0.0441). For both inhibitor and 
mimic conditions, miR-142-3p retinal levels were measured to assess its 
inhibition/overexpression (Supp. 2 & Supp. 3). Altogether, the modulation of miR-142-3p 
expression in CNV mouse model revealed a functional role of this microRNA during CNV 
progression. Intriguingly, both the vascular and microglia components of CNV lesions were 

















Figure 2. Inhibition of miR-142-3p in a laser-induced CNV mouse model decreases 
both vascular and inflammatory phenotypes.  
A OCT measurement presented as (b-c)/c ratios where b is the CNV lesion thickness and c is the adjacent 
choroid thickness. b and c were measured just prior to sacrifice (n = 23-29 per experimental group). B Flat-
mounted choroids showing vascular (in green) and microglia (in red) density and corresponding 
quantification. Scale bar = 250 µm (n = 14-15 per experimental group). All results are presented as mean +- 




Figure 3. Overexpression of miR-142-3p in a laser-induced CNV mouse model 
increases both vascular and inflammatory phenotypes.  
A OCT measurement presented as (b-c)/c ratios where b is the CNV lesion thickness and c is the adjacent 
choroid thickness. b and c were measured just prior to sacrifice (n = 24-26 per experimental group). B Flat-
mounted choroids showing vascular (in green) and microglia (in red) density and corresponding 
quantification. Scale bar = 250 µm (n = 11-13 per experimental group). All results are presented as mean +- 
SEM. Mann Whitney test (* = p ≤ 0.05) 
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Retina microglia cell activation is closely linked to miR-142-3p expression 
Microglia cells are resident immune cells of the central nervous system, including the 
retina. In laser-induced mouse model of CNV, microglia are recruited from the retina and 
invade the underlying CNV lesion [23, 24]. Under activation in inflammatory conditions, 
resting microglia cells lose their highly ramified morphology and gain an amoeboid shape. 
To assess the effect of miR-142-3p on retina microglia cell shape in vivo, an innovative 
computerized quantification method has been set up. Cell solidity corresponds to the ratio 
between the cell volume and its convex volume, and reflects microglia activation (Fig 4A). 
While activated amoeboid microglia cells are characterized by a solidity closer to 1 (which 
characterizes a round cell), resting ramified microglia cells are characterized by a solidity 
closer to 0 (Fig. 4A). Each portion of the whole retina corresponding to a CNV lesion and 
its surrounding tissue was imaged at the 20X magnification to insure an optimal resolution 
for cell solidity analysis (Fig. 4B). Raw images were processed and binarized for 
computerized quantification, which allowed a clear discrimination of every single microglia 
cell within the entire image (Fig. 4C and Supp. 4). Interestingly, this computerized image 
analysis revealed that miR-142-3p inhibitor and miR-142-3p mimic impacted drastically the 
morphology of retina microglia cell (Fig. 4D). While miR-142-3p inhibitor decreased 
microglia solidity and thus microglia activation, miR-142-3p mimic had the opposite effect. 



































































Figure 4. MiR-142-3p influences microglia cell activation state in vivo.  
A Characterization of microglia morphology via cell solidity. The solidity of an object is defined as the ratio 
between its volume and its convex volume. Resting microglia are highly ramified while activated microglia 
present an amoeboid shape, with no or small ramifications. Activated microglia are characterized by a higher 
solidity. B CNV lesion area of flat-mounted retinas and surrounding healthy tissue were imaged at the 20X 
magnification and then processed and quantified. C Representative raw images and corresponding labelled 
images of resting and activated microglia area. D Microglia activity measured around the CNV lesion in mice 
injected with either miR-142-3p inhibitor or mimic and relative controls (n = 5-10 per experimental group). All 
results are presented as mean +- SEM. Mann Whitney test (* = p ≤ 0.05; ** = p ≤ 0.01)  
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MiR-142-3p regulates the activation of human microglia cells under pro-
inflammatory conditions  
Transfection of human microglia HMC3 cells with miR-142-3p mimic drastically 
increased miR-142-3p expression (Fig. 5A, right panel). It also decreased the production of 
its previously described target, BCLAF1, both at mRNA (Fig. 5B, right panel) and protein 
(Fig. 5C) levels [25]. BCLAF1 was used here to validate the efficacy of miR-142-3p mimic. 
Alongside with its effect on BCLAF1 expression, miR-142-3p overexpression also 
influenced HMC3 activation state as assessed by increased CD68 level (Fig. 5D, right panel), 
a marker of microglia activation [26, 27]. Interestingly, VEGF-A transcript level (Fig. 5E, 
right panel) increased upon miR-142-3p mimic, which could contribute to the effect observed 
in vivo on the angiogenic response. When using the inhibitor, only a slight decrease of miR-
142-3p expression was observed (Fig. 5A, left panel) without any effect on BCLAF1, CD68 
and VEGF-A levels (Fig. 5 B-E, left panels). Such a low effect of the inhibitor may be related 
to the low basal level of miR-142-3p in HMC3 cell line.  
Our data in vitro confirm the in vivo findings of the biological implication of miR-142-
3p in microglia activation. This is further supported by the concomitant increase of miR-142-
3p and CD68 expressions in HMC3 cells stimulated by IFNg or LPS (Fig. 5F). Taken 



























































Figure 5. MiR-142-3p regulates the activation of human microglia cells under pro-
inflammatory conditions.  
A-C Transfections of miR-142-3p inhibitor and mimic lead to decreased and increased miR-142-3p level, 
respectively (A). Transfection of miR-142-3p mimic decreased BCLAF1 levels, a previously identified target 
of miR-142-3p, both at the transcript level (B) and protein level (C). D-E Effects on CD68 level (D) or VEGF-
A (E) in HMC3 transfected with miR-142-3p inhibitor or mimic and relative controls. Only miR-142-3p mimic 
was able to induce CD68 et VEGF-A production. F HMC3 stimulated with either IFN𝛾 or LPS for 24 hours 
overexpress miR-142-3p as long with CD68.All qRT-PCR results are presented as mean +- SEM. Mann 





The present study unveils a functional role of miR-142-3p in stimulating CNV formation 
in a mouse model of wet AMD. This novel concept is supported by i) the overexpression of 
miR-142-3p in CNV lesions, and by ii) the impact of this miRNA modulation 
(inhibition/overexpression) on both vascular and inflammatory phenotypes. While inhibition 
of miR-142-3p caused a subsequent decrease of angiogenesis, its overexpression had the 
opposite effect. Beside its effect on angiogenesis, administration of miR-142-3p activates 
microglia cells -part of the inflammatory process- both in vivo and in vitro. Our data provide 
evidence for a pivotal role played by miR-142-3p during CNV progression and particularly 
on microglia activation. 
The originality of our approach relies on the laser microdissection, which enables us to 
isolate CNV tissue devoid of any surrounding healthy tissue that could have biased the 
microRNA profile [28]. Indeed, previous studies in CNV mouse primarily investigated 
microRNAs circulating in the blood [17, 29] or present in the entire RPE-choroid-sclera 
complexes [30]. It is noteworthy that CNV lesion sites only englobe 2.5% of total choroid 
tissue, making entire choroid complexes highly heterogenous mixes of healthy and non-
healthy tissue. Among the microRNAs tested, 4 were dysregulated: miR-21-5p, miR-34a-5p 
and miR-142-3p increased, whereas miR-574-3p decreased upon laser-induction. In line with 
our data, miR-21-5p was previously reported as strongly up-regulated in RPE-choroid-sclera 
complex [30]. MiR-21-5p is a well-known pro-angiogenic microRNA in different 
pathologies [31, 32] and is highly abundant in human retinal endothelial cells [33]. 
Concomitantly to the overexpression of miR-34a-5p in our samples, this microRNA was 
found to be upregulated in serum of AMD patients [34] and in hydrogen peroxide-induced 
prematurely senescent ARPE-19 cells [35], possibly leading thus to AMD progression. 
Here, we identified miR-142-3p as a specific CNV lesion microRNA, being upregulated 
both 5- and 7-days post laser-induction and displaying a correlation with uPA, a well-
established CNV disease marker [22]. MiR-142 gene is a broadly conserved miRNA gene 
among species that gives rise to two distinct mature forms, miR-142-3p and miR-142-5p. 
MiR-142 is involved in stem cell fate, cardiomyocyte hypertrophy, cancer, immune tolerance 
and hematopoiesis, as previously reviewed [36]. Both vascular [25] and inflammatory [37] 
functions have been attributed to this microRNA. Interestingly, miR-142-3p expression is 
upregulated in a mouse model of retinal degeneration [38], but its biological role in ocular 
disease, including wet AMD, remained unknown. The increase of miR-142-3p in CNV goes 
in parallel with macrophage recruitment, as well as the increase in vascular density [7]. Thus, 
miR-142-3p expression was associated with two interconnected hallmarks of the disease, 
namely inflammation and angiogenesis. Previous studies revealed that the cellular source of 
miR-142-3p may be more immune-related rather than vascular-related [39-41]. Accordingly, 
miR-142-3p expression in human microglia cells increased upon IFNg or LPS stimulation, 
and correlated with CD68 level, a marker of activated microglia. To evaluate the functional 
role of miR-142-3p during CNV, miR-142-3p inhibitor or mimic were injected into the 
vitreous chamber of CNV mouse. Intravitreal injections are routinely used by clinicians to 
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deliver anti-VEGF drugs to wet AMD patients [42]. On one hand, intravitreal injection of 
miR-142-3p inhibitor decreased the vascular density in flat-mounted choroids, while 
injection of miR-142-3p mimic conversely increased it. Those findings were further 
confirmed by alterations of CNV lesion thickness measured via OCT. Furthermore, 
intravitreal miR-142-3p inhibition alleviated microglia density, while miR-142-3p mimic 
increased it.  
Microglia are the immune resident cells of the central nervous system, constantly 
screening their environment for pathogens and ready to migrate, proliferate and phagocyte if 
needed. In physiological conditions, retinal microglia cells exhibit a highly ramified 
morphology, shifting to a more amoeboid shape under activation [24]. In the laser-induced 
CNV context, microglia are known to migrate from retina and invade CNV lesion site, 
starting 4-days post laser-induction [23]. Various cellular morphology parameters exist to 
describe microglia shape [43, 44], but cell solidity has been described as the most appropriate 
one for assessing the amoeboid shape of activated microglia, and thus microglia activation 
[45]. An innovative computerized imaging and quantification technique revealed that miR-
142-3p inhibition/overexpression decreases/increases retinal microglia cell solidity in vivo, 
in line with our in vitro data of miR-142-3p mediated microglia activation. Our data suggest 
that miR-142-3p stimulates the activation of microglia in the retina and their migration to the 
CNV lesion site, located within the choroid. Accordingly, miR-142-3p is one of the top up-
regulated microRNA in primary microglia isolated from rat pup’s brain under LPS 
stimulation [46]. Besides morphological analysis, future studies may evaluate mouse 
microglia activation state through transcriptomic and surface marker analyses. Interestingly, 
in human microglia culture, miR-142-3p mimic enhanced drastically miR-142-3p levels, as 
well as CD68 expression, a marker of activated microglia [26, 27]. An interesting finding is 
the concomitant up-regulation of VEGF-A, a key molecular mediator of CNV progression 
[47]. This demonstrates that miR-142-3p is able to modulate both inflammatory and vascular 
responses, two intimately linked processes associated to CNV progression [48]. 
Interestingly, CD68 was also upregulated in HMC3 stimulated by IFNg or LPS, leading to a 
pro-inflammatory state [49, 50]. This observation supports the concept that miR-142-3p is a 
mediator of inflammation triggering microglia cell activation and is in line with our in vivo 
data. How miR-142-3p modulates CD68 and VEGF-A production remains to be elucidated. 
However, our data support the concept that miR-142-3p could be a new intermediate in the 
vascular-inflammatory axis during CNV progression, through microglia activation. 
In conclusion, miR-142-3p may exacerbate CNV by enhancing microglia migration and 











The authors kindly acknowledge Nathalie Lefin and Erika Konradowski for technical support 
and the GIGA Flow Cytometry and Cell Imaging Platform for their help for image 
acquisition and laser microdissection. This study was supported by a joined PhD funding 
program in the framework of the cooperation between the University of Liège and Maastricht 
University named “Towards a joint imaging valley”. Financial supports from Fondation Léon 
Fredericq, FEDER (BIOMED HUB – DMLA-AB), FNRS-PDR (grant number: T.1080.15) 
and “Fonds Spéciaux de l’Université de Liège” are gratefully acknowledged. This study has 
also been possible thanks to the support of the ERA-Net-CVD project MacroERA, 
01KL1706. The authors acknowledge the support from the Netherlands Cardiovascular 
Research Initiative, an initiative with support of the Dutch Heart Foundation, CVON2016-




Conflicts of interest 
 





Q.R. conceptualized the work, performed investigations, interpreted results and wrote the 
manuscript. J.L. conceptualized the work, performed investigations and reviewed and/or 
edited the manuscript. T.L., C.Y., L.B. and V.L. performed investigations and reviewed 
and/or edited the manuscript. V.C. and I.S. reviewed and/or edited the manuscript. A.N. and 


















1. WHO, World report on vision. 2019. 
2. Flaxman, S.R., et al., Global causes of blindness and distance vision impairment 
1990–2020: a systematic review and meta-analysis. The Lancet Global Health, 
2017. 5(12): p. e1221-e1234. 
3. Wong, W.L., et al., Global prevalence of age-related macular degeneration and 
disease burden projection for 2020 and 2040: a systematic review and meta-
analysis. The Lancet Global Health, 2014. 2(2): p. e106-e116. 
4. Adelman, R.A., E.J. Sigler, and R.K. Seth, Age-related Macular Degeneration—
Review and Current Concepts. US Ophthalmic Review, 2011. 04(01). 
5. Storey, P., L. Hark, and J.A. Haller, Age-Related Macular Degeneration, in 
Handbook of Nutrition, Diet and the Eye. 2014. p. 11-20. 
6. Fletcher, E.L., Contribution of microglia and monocytes to the development and 
progression of age related macular degeneration. Ophthalmic Physiol Opt, 2020. 
40(2): p. 128-139. 
7. Lambert, V., et al., Laser-induced choroidal neovascularization model to study 
age-related macular degeneration in mice. Nat Protoc, 2013. 8(11): p. 2197-211. 
8. Pennesi, M.E., M. Neuringer, and R.J. Courtney, Animal models of age related 
macular degeneration. Mol Aspects Med, 2012. 33(4): p. 487-509. 
9. Park, Y.G., et al., New Approach of Anti-VEGF Agents for Age-Related Macular 
Degeneration. J Ophthalmol, 2012. 2012: p. 637316. 
10. Zuber-Laskawiec, K., et al., Non-responsiveness and tachyphylaxis to anti-
vascular endothelial growth factor treatment in naive patients with exudative age-
related macular degeneration. J Physiol Pharmacol, 2019. 70(5). 
11. O'Brien, J., et al., Overview of MicroRNA Biogenesis, Mechanisms of Actions, and 
Circulation. Front Endocrinol (Lausanne), 2018. 9: p. 402. 
12. Gebert, L.F.R. and I.J. MacRae, Regulation of microRNA function in animals. Nat 
Rev Mol Cell Biol, 2019. 20(1): p. 21-37. 
13. Bartel, D.P., Metazoan MicroRNAs. Cell, 2018. 173(1): p. 20-51. 
14. Xu, S. and L.D. Hazlett, MicroRNAs in Ocular Infection. Microorganisms, 2019. 
7(9). 
15. Raghunath, A. and E. Perumal, Micro-RNAs and their roles in eye disorders. 
Ophthalmic Res, 2015. 53(4): p. 169-86. 
16. Ménard, C., et al., MicroRNA signatures in vitreous humour and plasma of 
patients with exudative AMD. Oncotarget, 2016. 7(15): p. 19171-84. 
17. Kiel, C., et al., A Circulating MicroRNA Profile in a Laser-Induced Mouse Model 
of Choroidal Neovascularization. Int J Mol Sci, 2020. 21(8). 
18. Liu, C.H., et al., MicroRNAs in Vascular Eye Diseases. Int J Mol Sci, 2020. 21(2). 
19. Marques-Rocha, J.L., et al., Noncoding RNAs, cytokines, and inflammation-
related diseases. FASEB J, 2015. 29(9): p. 3595-611. 
20. Tiwari, A., B. Mukherjee, and M. Dixit, MicroRNA Key to Angiogenesis 
Regulation: MiRNA Biology and Therapy. Curr Cancer Drug Targets, 2018. 18(3): 
p. 266-277. 
21. Schindelin, J., et al., Fiji: an open-source platform for biological-image analysis. 
Nat Methods, 2012. 9(7): p. 676-82. 
22. Rakic, J.M., et al., Mice without uPA, tPA, or plasminogen genes are resistant to 
experimental choroidal neovascularization. Invest Ophthalmol Vis Sci, 2003. 
44(4): p. 1732-9. 
 122
23. Crespo-Garcia, S., et al., In vivo analysis of the time and spatial activation pattern 
of microglia in the retina following laser-induced choroidal neovascularization. 
Exp Eye Res, 2015. 139: p. 13-21. 
24. Silverman, S.M. and W.T. Wong, Microglia in the Retina: Roles in Development, 
Maturity, and Disease. Annu Rev Vis Sci, 2018. 4: p. 45-77. 
25. Bao, H., et al., Platelet-derived microparticles promote endothelial cell 
proliferation in hypertension via miR-142-3p. FASEB J, 2018. 32(7): p. 3912-
3923. 
26. Costa, T., et al., Combined 1-Deoxynojirimycin and Ibuprofen Treatment 
Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration 
in MPTP-Treated Mice. J Neuroimmune Pharmacol, 2020. 
27. Stankov, A., et al., Visualisation of Microglia with the use of 
Immunohistochemical Double Staining Method for CD-68 and Iba-1 of Cerebral 
Tissue Samples in Cases of Brain Contusions. Pril (Makedon Akad Nauk Umet 
Odd Med Nauki), 2015. 36(2): p. 141-5. 
28. Hernandez, S. and J. Lloreta, Manual versus laser micro-dissection in molecular 
biology. Ultrastruct Pathol, 2006. 30(3): p. 221-8. 
29. Grassmann, F., et al., A circulating microrna profile is associated with late-stage 
neovascular age-related macular degeneration. PLoS One, 2014. 9(9): p. 
e107461. 
30. Zhang, L., et al., Differential Expressions of microRNAs and Transfer RNA-
derived Small RNAs: Potential Targets of Choroidal Neovascularization. Curr Eye 
Res, 2019. 44(11): p. 1226-1235. 
31. Du, X., et al., miR-21 induces endothelial progenitor cells proliferation and 
angiogenesis via targeting FASLG and is a potential prognostic marker in deep 
venous thrombosis. J Transl Med, 2019. 17(1): p. 270. 
32. Fan, B., et al., MicroRNA-21 contributes to renal cell carcinoma cell invasiveness 
and angiogenesis via the PDCD4/c-Jun (AP-1) signalling pathway. Int J Oncol, 
2020. 56(1): p. 178-192. 
33. Walz, J.M., et al., Impact of angiogenic activation and inhibition on miRNA 
profiles of human retinal endothelial cells. Exp Eye Res, 2019. 181: p. 98-104. 
34. Romano, G.L., et al., Retinal and Circulating miRNAs in Age-Related Macular 
Degeneration: An In vivo Animal and Human Study. Front Pharmacol, 2017. 8: p. 
168. 
35. Tong, N., et al., Involvement of microRNA-34a in Age-Related Susceptibility to 
Oxidative Stress in ARPE-19 Cells by Targeting the Silent Mating Type 
Information Regulation 2 Homolog 1/p66shc Pathway: Implications for Age-
Related Macular Degeneration. Front Aging Neurosci, 2019. 11: p. 137. 
36. Shrestha, A., et al., MicroRNA-142 is a multifaceted regulator in organogenesis, 
homeostasis, and disease. Dev Dyn, 2017. 246(4): p. 285-290. 
37. Mandolesi, G., et al., miR-142-3p Is a Key Regulator of IL-1beta-Dependent 
Synaptopathy in Neuroinflammation. J Neurosci, 2017. 37(3): p. 546-561. 
38. Huang, P., et al., MicroRNA Expression Patterns Involved in Amyloid Beta-
Induced Retinal Degeneration. Invest Ophthalmol Vis Sci, 2017. 58(3): p. 1726-
1735. 
39. Chaudhuri, A.D., et al., Up-regulation of microRNA-142 in simian 
immunodeficiency virus encephalitis leads to repression of sirtuin1. FASEB J, 
2013. 27(9): p. 3720-9. 
 123 
40. Carofino, B.L., et al., Head and neck squamous cancer progression is marked by 
CLIC4 attenuation in tumor epithelium and reciprocal stromal upregulation of 
miR-142-3p, a novel post-transcriptional regulator of CLIC4. Oncotarget, 2019. 
10(68): p. 7251-7275. 
41. Guiot, J., et al., Macrophage-derived exosomes attenuate fibrosis in airway 
epithelial cells through delivery of antifibrotic miR-142-3p. Thorax, 2020. 75(10): 
p. 870-881. 
42. Ba, J., et al., Intravitreal anti-VEGF injections for treating wet age-related 
macular degeneration: a systematic review and meta-analysis. Drug Des Devel 
Ther, 2015. 9: p. 5397-405. 
43. Young, K. and H. Morrison, Quantifying Microglia Morphology from 
Photomicrographs of Immunohistochemistry Prepared Tissue Using ImageJ. J Vis 
Exp, 2018(136). 
44. Damani, M.R., et al., Age-related alterations in the dynamic behavior of 
microglia. Aging Cell, 2011. 10(2): p. 263-76. 
45. Zanier, E.R., et al., Shape descriptors of the "never resting" microglia in three 
different acute brain injury models in mice. Intensive Care Med Exp, 2015. 3(1): 
p. 39. 
46. Gupta, N., et al., miR-142-3p Regulates BDNF Expression in Activated Rodent 
Microglia Through Its Target CAMK2A. Front Cell Neurosci, 2020. 14: p. 132. 
47. Kwak, N., et al., VEGF is major stimulator in model of choroidal 
neovascularization. Invest Ophthalmol Vis Sci, 2000. 41(10): p. 3158-64. 
48. Huang, H., et al., VEGF receptor blockade markedly reduces retinal 
microglia/macrophage infiltration into laser-induced CNV. PLoS One, 2013. 8(8): 
p. e71808. 
49. Martinez Leo, E.E. and M.R. Segura Campos, Neuroprotective effect from Salvia 
hispanica peptide fractions on pro-inflammatory modulation of HMC3 microglial 
cells. J Food Biochem, 2020. 44(6): p. e13207. 
50. Cappoli, N., et al., The mTOR kinase inhibitor rapamycin enhances the expression 
and release of pro-inflammatory cytokine interleukin 6 modulating the activation 



















 124  2 



























































































Supplementary Figure 1 Spearman correlation between uPA level and miR-142-3p level in 
















Supplementary Figure 2 Expression of miR-142-3p was measured in CNV mouse retinas 7 
days post laser-induction and intravitreal injection of miR-142-3p inhibitor and relative 















Supplementary Figure 3 Expression of miR-142-3p was measured in CNV mouse retinas 7 
days post laser-induction and intravitreal injection of miR-142-3p mimic and relative negative 
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Supplementary Figure 2 Expression of miR-142-3p was measured in CNV mouse retinas 7 
days post laser-induction and intravitreal injection of miR-142-3p inhibitor and relative 















Supplementa y Figure 3 Expression of miR-142-3p was measured in CNV mouse retinas 7 
days post laser-induction and intr vit eal injection of miR-142-3p mimic and relative negative 

































































































Supplem ntary Figure 1 Spearman correlation betwe n uP  l i -142-3p level in 
















Supplementary Figure 2 Expression of miR-142-3p was easured in CNV mouse r tinas 7 
days post laser-induction and intravitreal injection of miR-142-3p inhibitor and relative 















Supplementary Figur  3 Expression of miR-142-3p was measured in CNV mouse retin s 7 
days post laser-induction and intravitreal injection of miR-142-3p mimic and relative negative 











































Supplem ntary Figure 1.  
Spearman correlat between uPA level and m R-142-3p level in CNV lesion 7 days post laser induction (r = 
0.503: p = 0.144). 
Supplementary Figure 2.  
Expression of miR-142-3p was measured in CNV mouse retinas 7 days po t laser-induction and intravitreal 
injection of iR-142-3p inhibitor and relative negative con r l (n = 8 per experimental g up) (ns = not 
significa t). 
Supplementary Figure 3. 
Expression of miR-142-3p was me sured in CNV mouse retinas 7 days post laser-induction and intravitreal 
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Supplementary Figure 4 Workflow chart of image processing and quantification for 








































Supplementary Figure 4.  






















































































MicroRNA implication in AMD and DR 
 
The aims of this thesis were: 1) to evaluate the potential of ZSF1 rat as a model of 
diabetic retinopathy, 2) to identify dysregulated microRNAs in animal models of DR and 
AMD and 3) to explore whether the modulation of promising microRNA candidates 
identified under 2) were able to influence choroidal neovascularization.  
In Chapter 3, we demonstrate that ZSF1 rat model, despite showing precursor signs of 
DR within retinal vasculature, failed to trigger further DR progression. This resistance to 
retinopathy development prompted us to further decipher its underlying genetic regulation. 
We point out a set of potential protective genes (i.e. Neuropeptide Y and several crystallin 
genes) overexpressed in obese rats that might be responsible of ZSF1 rat resistance to DR 
development. In Chapter 4, we define a set of 5 angiogenesis and inflammation-related 
microRNAs whose expression was upregulated in both human vitreous of diabetic patients 
and retinas of Akimba mice, a model of advanced DR. We suggest that these microRNAs 
might be functional regulators of DR progression. Finally, in Chapter 5, we show that miR-
142-3p is a functional mediator of choroidal neovascularization, the hallmark of wet AMD. 
Intravitreal injections of miR-142-3p inhibitor and mimic in the laser-induced CNV mouse 
model highlighted the pro-angiogenic and pro-inflammatory effects of this poorly described 
microRNA. We particularly demonstrate a clear link between miR-142-3p and microglia 
activation, both in vivo and in vitro. 
 
Taken together, AMD and DR are responsible for the majority of blindness cases 
worldwide and are thus a major public health issue [1]. Often neglected, eye health is 
however crucial for maintaining a normal life. Half of the population consider losing vision 
as the worst possible health outcome [2]. Because no cure for AMD and DR is available, 
prevention remains the best strategy to avoid detrimental sight decrease. Thus, lowering 
AMD and DR risk by quitting or (best) not starting smoking, practicing regular exercise, 
having a healthy diet and controlling diabetes are the main everyday life modifiable risk 
factors [3-5]. AMD and DR show distinct pathophysiology but share biological features, 
namely inflammation and angiogenesis. This results in similar current treatment strategy for 
advanced AMD and DR, i.e. intravitreal injections of anti-VEGF drugs. Despite having been 
a revolution in AMD treatment a couple decades ago and reducing blindness incidence in 
AMD patients [6], anti-VEGF therapy now shows its limitations and an urgent clinical need 
for new therapies has emerged [7]. Moreover, repeated intravitreal injections are often 
painful and/or stressful for patients [8] and anti-VEGF drugs, despite showing discrepancies 
between molecules, are often quite expensive [9]. These medical, psychological and 
economic impacts should lead to the development of new drugs. While several clinical trials 
assessing microRNAs as targets are currently under process for different cancer types, no 
microRNA entered yet a clinical trial for ocular pathologies (Table 1) [10, 11]. With 
increasing evidence of microRNA functionality in eye diseases, opportunities for clinical 



































miRNA target Drug  
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Inhibitor Alport Syndrome Phase I 
miR-29 Remlarsen 
(MRG-201) 
Mimic Fibrous scar formation Phase II 
miR-34 MRX34 Mimic Primary liver cancer Phase I 
miR-92 MRG-110 LNA inhibitor Wound healing Phase I 
miR-122 Miravirsen LNA inhibitor Hepatitis C virus Phase I/II 
miR-155 Cobomarsen 
(MRG-106) 




Limitations of the study & perspectives 
 
With this work, we provide evidence for the use of ZSF1 rat model as a model of 
resistance to DR onset, as well as the use of microRNAs as promising therapeutic targets in 
different ocular pathologies. However, several perspectives might be considered for further 
investigations and deeper characterization. Also, several technical limitations have to be 
considered in regard to the interpretation of the presented results. 
 
Regarding the ZSF1 rat model, we were able to highlight several genes that might be 
responsible for the apparent resistance to DR development. First, including more phenotypic 
readouts for DR onset such as histology on retinal sections, counting of pericyte cells (instead 
of pericyte coverage), microglia morphology analysis (instead of only number) and light-
sheet microscopy of full eyeballs may be of valuable interest to have an overall view of ZSF1 
rat retina phenotype. While we investigated gene dysregulation in ZSF1 rats, we did not 
consider a microRNA analysis. Having a microRNA expression analysis on ZSF1 rat retinas 
could help us to further understand the surprising lack of DR phenotype in this diabetic 
animal model. We could expect that some microRNAs upregulated in the Akimba mice 
might be downregulated in ZSF1 rats. Thus, these microRNAs, upregulated in model of DR 
and downregulated in model of resistance to DR, might have functional implications in 
retinopathy onset. It would be of particular interest to analyze the expression pattern of miR-
142-3p over age in ZSF1 rats. Moreover, we analyzed gene expression only at the first and 
latest ages, but having a more precise view by analyzing intermediate timepoints could also 
bring some answers. Finally, the difference that we observed in arteriolar tortuosity and Crys 
genes family may eventually be obesity related and thus linked to the leptin receptor mutation 


















Regarding the human vitreous and Akimba mouse model study, several perspectives 
might be considered. 
 First, increasing the cohort of diabetic patients and enlarging it by recruiting DR patients 
would be necessary to conclude of microRNAs expression in human samples of DR. Indeed, 
we were able to conduct our qRT-PCR screening only on a low number of human samples, 
and thus might not sufficiently reflect human pathology. This low number of samples may 
also explain why only upregulated microRNAs were highlighted while no significant 
downregulation was observed. Individual variability was consequent in regards to 
microRNA expression, in both healthy and diabetic groups. Increasing patient cohort may 
reduce this unwanted variability. Moreover, collecting other types of human samples, such 
as blood or post-mortem eyeballs, would be of particular interest. Regular access to blood 
samples from healthy controls and DR patients during their clinical follow-up would allow 
to evaluate how microRNA expression changes in response to treatment. Collecting fresh 
post-mortem human eyeballs could allow us to evaluate microRNA expression in the retina 
and eventually choroid of DR patients.   
In a second time, assessment of microRNA function in the Akimba mice by intravitreal 
or systemic injections of microRNA inhibitors and mimics would be of particular interest. 
Despite we showed microRNA dysregulation in Akimba retinas, we did not bring any proof 
of functionality. Thus, in vivo microRNA modulation might be considered for further 
characterization. Also, assessing Crys and Npy genes expression in Akimba mice and 
parental strains may allow to further confirm their implication in DR onset. However, the 
Akimba mouse being under a patent protection, it is hardly accessible for academic purposes. 
To overcome the technical limitation of Akimba accessibility, the use of another DR animal 
model may be considered. Using the well-established and easily manageable STZ-induced 
model may be relevant. Moreover, this model mainly reflecting the early DR stage, and thus 
mainly the inflammatory processes, it could be useful to better determine whether miR-142-
3p is more inflammation or angiogenesis-related. Finally, evaluating in vitro diverse cellular 
functions, such as proliferation, migration and phagocytosis activity of microglia cells by 
mimicking DR onset with high or low glucose culture conditions, or by modulating the 
expression of most promising microRNAs could help to decipher the tight regulation 












Regarding the role of miR-142-3p during CNV progression, we provide first evidence 
of this microRNA as a therapeutic target for AMD. However, specific microglia activation 
should be first further confirmed and then, mechanistic information on microglia activation 
by miR-142-3p might be needed.  
To address the first question, a deeper molecular analysis of microglia may be 
performed, both in vivo and in vitro. In the laser-induced CNV model, the extended use of 
microglia-specific markers such as TMEM19 or P2Y12 should be considered in order to 
allow a clear discrimination between resident microglia and infiltrating macrophages. 
Combining the use of classical Iba1 marker and CD45 expression profile may also be 
considered. Despite being relevant, morphological analysis of microglia activation may be 
combined with molecular approaches. Thus, evaluating expression levels of different surface 
markers such as CD14 and CD16, specific to M1 activated microglia, from retinal isolated 
microglia may further confirm miR-142-3p implication in microglia activation. In vitro, the 
same markers should be used to confirm microglia activation, on both primary microglia and 
well-established cell line such as HMC3 (human) and BV2 (murine) cells. 
To address the mechanistic information, several perspectives may be considered. Thus, 
in vitro assessment of microglia proliferation, migration, phagocytosis activity and cytokines 
production under modulation of miR-142-3p could help us to better understand the way this 
microRNA is able to regulate inflammation and angiogenesis in vivo. Interactions between 
endothelial cells and microglia cells should also be studied since miR-142-3p acts at both 
vascular and inflammatory sides. Moreover, despite showing a clear link between miR-142-
3p expression and microglia activation, we did not show the cellular source of miR-142-3p. 
To do so, in situ hybridizations could help in determining which cell type produces miR-142-
3p. However, being a really low abundant microRNA, in situ hybridization are technically 
challenging. Also, despite showing an effect of BCLAF1 expression, a previously described 
miR-142-3p target, we do not show any functional direct target of miR-142-3p that might be 
responsible of microglia activation and decreased vascular phenotype. Cross analysis of 
RNA-sequencing data from laser-induced CNV mouse model and target databases (such as 
TargetScan and miRTarBase) might highlight target genes whose function could be linked 
to observed phenotypes. Optimization of inhibitor and mimic concentration for intra-vitreal 
injections, bioavailability as well as diffusion of these molecules within the mouse eye should 
be considered. Despite we observed an effect by injecting these molecules with no carrier, 
including the molecule in exosomes or other type of vesicles may increase tissue penetration 
and thus efficiency.  
Finally, despite showing a beneficial effect of miR-142-3p inhibition on CNV 
progression, its efficiency should be compared to current standard of care treatments (i.e. 









The data presented in this thesis take us a step closer to an understanding on the 
implication and contribution of microRNAs in diabetic retinopathy and age-related macular 
degeneration. It appears clear from this doctoral work that microRNAs regulate several 
ocular pathologies and might be considered as targets for new clinical therapeutic strategies. 
However, the use of a miR-targeting strategy in the clinic implies a deeper characterization 
and actual molecular regulation by microRNAs of such diseases, as well as safety analysis, 
target optimization and pharmaco-kinetics and dynamics studies. MicroRNAs having 
pleiotropic functions on diverse genes sets, these tiny molecules should be considered as 
double-edged swords: great clinical applications come along with potential harmful side-
effects. Overall, this work could be a resource to fuel future investigations on targeting 
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“The eye as a miRror: targeting microRNAs in ocular pathologies” is a doctoral work 
performed by Quentin Roblain from February 2017 to January 2021 in collaboration between 
the University of Liège, Belgium (under the supervision of Prof. Dr. Agnès Noël) and 
Maastricht University, The Netherlands (under the supervision of Prof. Dr. Stephane 
Heymans). The main goal of this doctoral work was to evaluate the biological implication of 
microRNAs during age-related macular degeneration (AMD) and diabetic retinopathy (DR). 
 
Vision impairment and blindness affect 2.2 billion individuals worldwide. Despite 
causing no direct death, vision impairment increases by a factor 3 the risk of being involved 
in a vehicle collision, the likelihood of suffering from depression and being unemployed. It 
also doubles the risk of having a fall while walking. AMD and DR are two vision-threatening 
eye disorders which are currently treated by intravitreal delivery of anti-VEGF drugs. 
However, patients exhibit great discrepancies in response to this treatment, and no cure for 
AMD and DR are available. MicroRNAs, a class of non-coding RNAs, have diverse 
biological functions during development, normal physiology and pathophysiology. These 
molecules could thus eventually be promising therapeutic targets in eye pathologies. In this 
work, the biological implication of microRNAs during AMD and DR was evaluated. In 
Chapter 1, every notion needed for a comprehensive reading of subsequent chapters is 
introduced, reviewed and summarized, microRNAs being the common thread between 
sections. Thus, a focus is made on their biology, their implication in the developing and adult 
eye, as well as in the pathological eye and finally, their role in microglia cells. In Chapter 
2, the suitability of ZSF1 rat model as a model of DR is evaluated. Despite showing 
hyperglycemia an increased arteriolar tortuosity, the ZSF1 rats failed to develop further 
diabetic retinopathy. A potential genes network is next highlighted, possibly preventing 
ZSF1 rats from developing DR. In Chapter 3, an expression profile of microRNAs in human 
and mouse samples and their potential as biomarker or therapeutic target in DR is made and 
discussed. In Chapter 4, specific overexpression of miR-142-3p is revealed in CNV lesion 
of a mouse model of choroidal neovascularization. Implication of miR-142-3p in activation 
of microglia cells both in vitro and in vivo is next demonstrated. Finally, in Chapter 5, a 
global discussion of the present work is made, as well as suggestions of perspectives that 
might be considered for a better understanding of microRNAs implication in AMD and DR. 
 
In conclusion, this doctoral work presents biological contributions of microRNAs in two 
eye pathologies, namely age-related macular degeneration and diabetic retinopathy. These 
findings extend the current knowledge on AMD and DR pathophysiology, and may 








• Socio-economic relevance 
Vision impairment and blindness affect 2.2 billion people worldwide and, in Europe, its 
estimated cost is 25.83 billion euros. Moreover, besides their large contribution to the global 
healthcare system cost, vision impairment and blindness can have a profound psychological 
impact on affected individuals, as well as on their quality of life. The use of available cost-
effective treatment and prevention strategies may significantly reduce both financial and 
social burdens. However, developing more efficient and less expensive drugs may also help 
with reducing vision impairment and blindness contribution to public health. In particular, 
despite a great progress in AMD and DR treatment since the approval of anti-VEGF therapy, 
these two retinal diseases are still not curable. Thus, a better understanding of AMD and DR 
biology is needed for the development of innovative drugs. In this regard, a close 
collaboration between basic scientists and clinicians is required, and will in the end be 
beneficial for patients. 
 
• Target groups 
The content of this doctoral work is broadly relevant for the scientific and academic 
communities. It may be of particular interest for other scientists working in the field of 
experimental ophthalmology, as well as for any other researcher whose area of study includes 
microRNAs. Since miR-142-3p implication in inflammation and microglia activation has 
been demonstrated in this doctoral work, it may also interest any scientists focused on other 
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• Innovation 
This project highlights the potential of microRNAs as therapeutic targets in the context 
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for the treatment of ocular diseases in a patent protection could be relevant if stronger proof 
of efficiency is provided.  
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